



**HAL**  
open science

## **Genetic screening of LCA in Belgium: predominance of CEP290 and identification of potential modifier alleles in AHI1 of CEP290-related phenotypes**

Frauke Coppieters, Ingele Casteels, Françoise Meire, Sarah de Jaegere, Sally Hooghe, Nicole van Regemorter, Hilde van Esch, Aušra Matulevičienė, Luis Nunes, Valérie Meersschaut, et al.

### ► To cite this version:

Frauke Coppieters, Ingele Casteels, Françoise Meire, Sarah de Jaegere, Sally Hooghe, et al.. Genetic screening of LCA in Belgium: predominance of CEP290 and identification of potential modifier alleles in AHI1 of CEP290-related phenotypes. *Human Mutation*, 2010, 31 (10), <10.1002/humu.21336>. <hal-00613751>

**HAL Id: hal-00613751**

**<https://hal.science/hal-00613751v1>**

Submitted on 6 Aug 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization



**Genetic screening of LCA in Belgium: predominance of  
*CEP290* and identification of potential modifier alleles in  
*AHI1* of *CEP290*-related phenotypes**

Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2010-0042.R1
Wiley - Manuscript type:	Mutation in Brief
Date Submitted by the	18-Jun-2010

<p>Complete List of Authors:</p>	<p>Coppieters, Frauke; Ghent University Hospital, Center for Medical Genetics  Casteels, Ingele; Leuven University Hospitals, Department of Ophthalmology  Meire, Françoise; Hôpital Des Enfants Reine Fabiola, Ophthalmology  De Jaegere, Sarah; Ghent University Hospital, Center for Medical Genetics  Hooghe, Sally; Ghent University Hospital, Center for Medical Genetics  Van Regemorter, Nicole; Free University of Brussels, Centre de Génétique de Bruxelles  van Esch, Hilde; University Hospital Leuven, Centre for Human Genetics  Matulevičienė, Aušra; Vilnius University, Department of Human and Medical Genetics  Nunes, Luis; Hospital Dona Estefânia Rua Jacinta Marto, Service of Medical Genetics  Meersschaut, Valérie; Ghent University Hospital, Department of Radiology  Walraedt, Sophie; Ghent University Hospital, Department of Ophthalmology  Standaert, Lieve; Revalidation Center Spermalie  Coucke, Paul; Ghent University Hospital, Dpt. Medical Genetics - Head Collagen Lab  Hoeben, Heidi; Middelheim Hospital, Department of Nephrology  Kroes, Hester; University Medical Center, Department of Biomedical Genetics  Vande Walle, Johan; Ghent University Hospital, Department of Pediatrics  de Ravel, Thomy  Leroy, Bart; Ghent University Hospital, Department of Ophthalmology  De Baere, Elfride; Ghent University Hospital, Center for Medical Genetics</p>
<p>Key Words:</p>	<p>LCA, CEP290, genotype-phenotype correlation, modifiers, AHI1</p>



MUTATION IN BRIEF

HUMAN MUTATION

For Peer Review

Received <date>; accepted revised manuscript <date>.

© 2010 WILEY-LISS, INC.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Genetic screening of LCA in Belgium: predominance of *CEP290* and identification of potential modifier alleles in *AH1* of *CEP290*-related phenotypes



Frauke Coppieters<sup>1</sup>, Ingele Casteels<sup>2</sup>, Françoise Meire<sup>3</sup>, Sarah De Jaegere<sup>1</sup>, Sally Hooghe<sup>1</sup>, Nicole van Regemorter<sup>4</sup>, Hilde Van Esch<sup>5</sup>, Aušra Matulevičienė<sup>6</sup>, Luis Nunes<sup>7</sup>, Valérie Meersschaet<sup>8</sup>, Sophie Walraedt<sup>9,10</sup>, Lieve Standaert<sup>10</sup>, Paul Coucke<sup>1</sup>, Heidi Hoeben<sup>11</sup>, Hester Y. Kroes<sup>12</sup>, Johan Vande Walle<sup>13</sup>, Thomy de Ravel<sup>5</sup>, Bart P. Leroy<sup>1,9,#</sup>, Elfride De Baere<sup>1,#</sup>

<sup>1</sup>Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium; <sup>2</sup>Department of Ophthalmology, Leuven University Hospitals, Leuven, Belgium; <sup>3</sup>Hôpital Des Enfants Reine Fabiola, Brussels, Belgium; <sup>4</sup>Centre de Génétique de Bruxelles, Free University of Brussels, Brussels, Belgium; <sup>5</sup>Centre for Human Genetics, Leuven University Hospitals, Leuven, Belgium; <sup>6</sup>Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; <sup>7</sup>Service of Medical Genetics, Hospital Dona Estefânia Rua Jacinta Marto, Lisboa, Portugal; <sup>8</sup>Department of Radiology, Ghent University Hospital, Ghent, Belgium; <sup>9</sup>Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium; <sup>10</sup>Revalidation Center Spermaie, Bruges, Belgium; <sup>11</sup>Department of Nephrology, Middelheim Hospital, Antwerp, Belgium; <sup>12</sup>Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands; <sup>13</sup>Department of Pediatrics, Ghent University Hospital, Ghent, Belgium; #Equal contribution

\*Correspondence to E. De Baere, MD, PhD, Phone: +32-9-3325186. Fax: +32-9-3326549. Email: Elfride.DeBaere@UGent.be

Contract grant sponsor: Research Foundation – Flanders (KAN 1.5.174.09, 01F01206, 3F001206, OZP 3G004306); Bijzonder Onderzoeksfonds (BOF06\_Asp\_FC UGent); Fund for Research in Ophthalmology.

Communicated by <Please don't enter>

**ABSTRACT:** Leber Congenital Amaurosis (LCA), the most severe inherited retinal dystrophy, is genetically heterogeneous, with 14 genes accounting for 70% of patients. Here, 91 LCA probands underwent LCA chip analysis and subsequent sequencing of 6 genes (*CEP290*, *CRB1*, *RPE65*, *GUCY2D*, *AIP1* and *CRX*), revealing mutations in 69% of the cohort, with major involvement of *CEP290* (30%). In addition, 11 patients with early-onset retinal dystrophy (EORD) and 13 patients with Senior-Loken syndrome (SLS), LCA-Joubert syndrome (LCA-JS) or cerebello-oculo-renal syndrome (CORS) were included. Exhaustive re-inspection of the overall phenotypes in our LCA cohort revealed novel insights mainly regarding the *CEP290*-related phenotype. The *AH1* gene was screened as a candidate modifier gene in three patients with the same *CEP290* genotype but different neurological involvement. Interestingly, a heterozygous novel *AH1* mutation, p.Asn811Lys, was found in the most severely affected patient. Moreover, *AH1* screening in five other patients with *CEP290*-related disease and neurological involvement revealed a second novel missense variant, p.His758Pro, in one LCA patient with mild mental retardation and autism. These two *AH1* mutations might thus represent neurological modifiers of *CEP290*-related disease. ©2010 Wiley-Liss, Inc.

**KEY WORDS:** LCA, *CEP290*, *AH1*, modifier, genotype-phenotype correlation

Deleted: earliest form of all

Deleted: ies

Received <date>; accepted revised manuscript <date>.

© 2010 WILEY-LISS, INC.

## INTRODUCTION

Leber Congenital Amaurosis (LCA, MIM[204000]) was first described as a congenital type of retinitis pigmentosa (RP). Approximately 20% of all blind children are thought to suffer from this disease. Phenotypic features include a congenital onset, severely reduced or absent electroretinogram (ERG), nystagmus, the oculo-digital sign, and a fundus aspect varying from normal to severely atrophic. Two main types of LCA have been reported, based on the presence or absence of photophobia, night blindness, hyperopia, macular/peripheral retinal abnormalities and measurable visual acuity (Hanein et al., 2004; Hanein et al., 2006). LCA displays variable expression, and seems to represent the extreme and severe end of a spectrum of inherited retinal disease.

LCA is predominantly inherited in an autosomal recessive manner. So far, one locus - *LCA9* (Keen et al., 2003) - and the following 14 genes have been identified: *GUCY2D* (Perrault et al., 1996), *RPE65* (Marlhens et al., 1997), *CRX* (Freund et al., 1998), *AIPL1* (Sohocki et al., 2000a), *RPGRIPI* (Dryja et al., 2001), *CRB1* (den Hollander et al., 2001), *RDH12* (Perrault et al., 2004), *IMPDH1* (Bowne et al., 2006), *CEP290* (den Hollander et al., 2006), *RD3* (Friedman et al., 2006), *LCA5* (den Hollander et al., 2007) and *SPATA7* (Wang et al., 2009), with the involvement of *TULP1* (Hagstrom et al., 1998) and *LRAT* (Thompson et al., 2001) under debate. Mutations in these genes account for ~70% of all LCA cases. Several of them are also implicated in other retinal dystrophies: *CRB1*, *RPE65*, *RDH12* and *SPATA7* are associated with both LCA and early-onset retinal dystrophy (EORD), which often overlap (Gu et al., 1997; den Hollander et al., 1999; Janecke et al., 2004; Wang et al., 2009).

Several subtypes of LCA can be considered part of the ciliopathies, as four disease genes - *TULP1*, *RPGRIPI*, *CEP290* and *LCA5* - encode ciliary proteins. Since cilia are present throughout the whole body, mutations in these genes may cause a broad phenotypic spectrum. One of the best examples is *CEP290*, the most frequently mutated gene in the western European LCA population. In addition to LCA, *CEP290* is associated with Joubert syndrome (JS, MIM[213300]), Senior-Loken syndrome (SLS, MIM[266900]), Meckel-Grüber syndrome (MKS, MIM[249000]) and Bardet-Biedl syndrome (BBS, MIM[209900]); a range of clinically and genetically heterogeneous ciliopathies (Sayer et al., 2006; Valente et al., 2006b; Baala et al., 2007; Brancati et al., 2007; Helou et al., 2007; Leitch et al., 2008). Recent studies suggest that modifiers may play a role in the pathogenesis of ciliopathies (Leitch et al., 2008; Khanna et al., 2009; Louie et al., 2010).

Establishing a molecular diagnosis for LCA is not only important in the context of genetic counselling and clinical prognosis, but is also essential in view of future gene therapy. Recent Phase I clinical trials for *RPE65* gene replacement therapy provide hopeful prospects for the treatment of inherited retinal dystrophies (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Cideciyan et al., 2009; Maguire et al., 2009). As such therapies are likely to be gene-specific, the development of robust clinical testing and efforts toward gene identification are of utmost importance.

Current diagnostic testing for LCA generally involves chip analysis that contains known mutations in the known LCA and EORD genes (Asper Ophthalmics, Estonia). Depending on the population, causal mutations are found in approximately 55% of all cases (Yzer et al., 2006). Only a limited number of laboratories subsequently screen an additional number of genes (Stone, 2007; den Hollander et al., 2008).

This study includes an extensive genetic survey in order to identify the molecular cause in 91 LCA probands mainly of Belgian origin, using LCA chip analysis for 8 to 13 genes and subsequent sequencing of the following genes: *CEP290* (MIM[610142]), *CRB1* (MIM[604210]), *RPE65* (MIM[180069]), *GUCY2D* (MIM[600179]), *AIPL1* (MIM[604392]) and *CRX* (MIM[602225]). In addition, exhaustive phenotyping was performed in all patients carrying mutation(s), and the *AHII* gene was screened for modifier alleles of *CEP290*-related disease.

## MATERIALS AND METHODS

## Patients

Ninety-one consenting subjects initially diagnosed with LCA were referred for molecular testing by an ophthalmologist and/or geneticist, mainly associated with the University Hospitals of Ghent, Leuven or Brussels. Eleven probands are born from a consanguineous marriage. The inclusion criteria for LCA were bilateral visual loss before the age of 6 months accompanied by nystagmus and an undetectable or significantly reduced ERG.

- Deleted: after birth
- Deleted: s
- Deleted: normal to pigmented
- Deleted: severe
- Deleted: in the large majority of cases
- Deleted: 1
- Deleted: 5
- Deleted: loci
- Deleted: (14 genes) were
- Deleted: , *LCA9* (Keen, et al., 2003)
- Deleted: in the identified
- Deleted: approximately
- Deleted: these genes
- Deleted: RP
- Deleted: The involvement
- Deleted: of *TULP1*, *RPGRIPI*, *CEP290* and *LCA5* in
- Deleted: the pathogenesis of
- Deleted: LCA suggests that LCA is one of the ciliopathies, an emerging group of disorders
- Deleted: caused by mutations in
- Deleted: associated with genes encoding ciliary proteins.
- Deleted: perspectives
- Deleted: early-onset RP
- Deleted: 6
- Deleted: (
- Deleted: )
- Deleted: Thus, gene-specific contributions to LCA in the population under study were established, and 26 novel mutations were identified. In addition, exhaustive phenotyping led to novel insights mainly into the natural history of retinal and extra-ocular features of *CEP290*-related LCA. Finally, potential modifiers of neurological involvement in *CEP290*-related disease were identified.
- Deleted: families
- Deleted: and

## 4 Coppieters et al.

Twelve patients presented with additional mental retardation and/or autistic behaviour. For 18 patients with an available Magnetic Resonance Imaging (MRI), the absence of a molar tooth sign (MTS) excluded the diagnosis of JS. In addition, genotyping was performed on 11 probands with EORD, (disease diagnosed beyond the first six months of life but before the age of three) and 13 with a retinal dystrophy in the context of JS (LCA-JS), SLS or cerebello-oculo-renal syndrome (CORS). These patients were not included during calculations of gene-specific contributions in isolated LCA. Genomic DNA and RNA were extracted from leukocytes using the Puregene DNA isolation kit (Gentra, Minneapolis, USA) and the RNeasy Mini kit (Qiagen) respectively, followed by cDNA synthesis with the iScript cDNA Synthesis kit (Bio-Rad). If available, parents and/or siblings were also genotyped. Seven of the patients were reported previously (Yzer et al., 2006; Brancati et al., 2007; Perrault et al., 2007). Patient notation was performed according to their clinical diagnosis (prefixes LCA, SLS, LCA-JS, CORS and EORD), with consecutive numbering in the order of the genes involved.

## Genotyping

As a pre-screening method, all patients with either isolated LCA or EORD were analysed with a microarray containing 344 to 641 mutations in 8 (*GUCY2D*, *CRX*, *RPE65*, *CRB1*, *RPGRIP1*, *AIPL1*, *LRAT* and *MERTK*) to 13 (addition of *TULP1*, *LCA5*, *RDH12*, *CEP290* and *SPATA7*) LCA and EORD genes (LCA chip Versions 2004-2009; Asper Ophthalmics, Estonia) (<http://www.asperbio.com>) (Zernant et al., 2005). Each of the mutations found by the LCA chip was subsequently confirmed through Sanger sequencing. In case of a heterozygous mutation, the coding exons and intron-exon boundaries of the involved gene were sequenced.

Patients in whom no mutations were identified after LCA chip analysis were analysed through sequencing of all coding exons and intron-exon boundaries of *CEP290*, *CRB1*, *RPE65*, *GUCY2D*, *AIPL1* and *CRX*, the first five genes being the most frequently mutated in LCA. At the time the LCA chip did not yet include *CEP290* variants, stepwise targeted mutation analysis was performed prior to sequencing of the total coding region. We initially screened for the frequent c.2991+1655A>G mutation followed by four additional mutations: c.4723A>T (p.Lys1575X), c.5587-1G>C (splice site), c.5163del (p.Thr1722GlnfsX2) and c.3310-1\_3310delinsAA (splice site). The first three mutations occurred multiple times in a previous study (Perrault et al., 2007); the latter was found in three patients with a heterozygous c.2991+1655A>G mutation in our population. *CEP290* was also screened at cDNA level in patients with only a single mutation in *CEP290*. To this end, cDNA screening using 16 overlapping primer sets was optimized. Four patients with *CEP290*-related LCA who presented with mental retardation, two patients with SLS, one patient with CORS and one patient with LCA-JS underwent sequencing of the *AHII* gene. For 13 patients with SLS/LCA-JS/CORS, molecular testing of *CEP290* was requested. Supp. Table S1 includes all primer sequences used in this study.

## Mutation nomenclature

Mutation nomenclature uses numbering with the A of the initiation codon ATG as +1 (www.hgvs.org/mutnomen), based on the following RefSeqs: NM\_201253.1 (*CRB1*), NM\_000329.2 (*RPE65*), NM\_000180.3 (*GUCY2D*), NM\_014336.3 (*AIPL1*), NM\_000554.4 (*CRX*), NM\_025114.3 (*CEP290*), NM\_152443.2 (*RDH12*), NM\_020366.3 (*RPGRIP1*) and NM\_001134831.1 (*AHII*) (<http://www.ncbi.nlm.nih.gov/nuccore>). All mutations and variants found in *CEP290* were submitted to the Locus-Specific Mutation Database *CEP290base* (<http://medgen.ugent.be/cep290base>) (Coppieters et al., 2010).

## Evaluation of sequence changes

The presence of all mutations was confirmed on a second PCR product. Segregation analysis of disease alleles was performed if possible. Genomic DNA obtained from > 340 unrelated ethnically matched healthy individuals was used as a control panel. Thorough bio-informatic evaluation of novel variants was done using Alamut software (v.1.5). Variants were designated as "unclassified variant (UV)" if no consensus was seen in all prediction programs used. The Alamut output for missense changes was listed in Supp. Table S2.

## Clinical evaluation of patients

After identification of the molecular cause, the clinical records were revisited, based on a clinical checklist comprising data on visual function, retinal appearance and associated (extra-) ocular features. When possible, ERG, fundus pictures, autofluorescence (AF) images and optical coherence tomography (OCT) were obtained. In

Deleted: of the LCA

Deleted: all

Deleted: early-onset retinal dystrophy (

Deleted: ,

Deleted: (Table 1)

Deleted: early-onset RP

Deleted: sequencing was performed of

Deleted: whole

Deleted: region

Deleted: Sanger

Deleted: the following genes:

Deleted: .

Deleted: T

Deleted: are

Deleted: genes

Deleted: CRX

Deleted: who

Deleted: carried

Deleted: was analyzed

Deleted: Five

Deleted: and

Deleted: Sanger

Deleted: 12

Deleted: All primer sequences used in this study are available on request.

Deleted: 170

Deleted: (Table 1)

Deleted: identifying

case of *CEP290*-related LCA, neurological (MRI) and nephrological data (kidney ultrasound [US], urinary and blood parameters) were obtained and evaluated.

## RESULTS

### Mutation screening strategy of known LCA genes

As a first step, 102 probands were subjected to LCA chip analysis (91 LCA and 11 EORD). In total, 30 sequence changes assigned as mutations by Asper Ophthalmics were identified in 47 individuals. Homozygous and compound heterozygous variants in one gene were each found in 13 patients; a single heterozygous variant was identified in 17 individuals. In addition, variants within two distinct genes were found in four patients. The zygosity of p.Glu1330X (*CRBI*) could not be determined in LCA-36. Confirmation of each mutation through direct sequencing identified two inconsistencies. At first, LCA-58 was genotyped heterozygously for the *AIPLI* mutation p.Trp278X by chip, while she was in fact homozygous. Secondly, a heterozygous p.Arg38AlafsX3 mutation in *AIPLI* (LCA chip version 2006) could not be confirmed in LCA-23. Instead, a heterozygous c.111C>T (p.=) variant was identified on the same nucleotide position. This miscall has previously been described (Henderson et al., 2007). In addition, subsequent sequencing of *GUCY2D* in LCA-51 revealed a heterozygous c.389del mutation that was not detected on the LCA chip. The variants c.2101C>T (p.Pro701Ser) (*GUCY2D*), c.3341A>G (p.Asp1114Gly) (*RPGRIP1*) (Vallespin et al., 2007a), c.286G>A p.Val96Ile (*AIPLI*) (Yzer et al., 2006) and c.1301C>T (p.Ala434Val) (*RPE65*) (Morimura et al., 1998) have already been reported as polymorphisms and were therefore discarded as mutations. Moreover, identification of the *GUCY2D* p.Pro701Ser variant in a homozygous state in both healthy parents from an LCA patient further supported its non-pathogenic nature. After the exclusion of these polymorphisms, variants were assigned to be mutations in 45 patients (39 LCA and 6 EORD).

Secondly, all patients with a heterozygous mutation identified through chip analysis were subjected to screening of the relevant gene. In addition, all patients with negative chip results underwent sequencing of 6 LCA genes. In the following sections, the molecular results are discussed in detail for each of the genes.

*CEP290*. *CEP290* was found to be the most frequently mutated gene in our cohort, accounting for 30% (27/91) of cases with isolated LCA (Table 1). Since the LCA chip did not contain *CEP290* variants at the onset of this study, only a fraction of currently known mutations were detected using this technique. The c.2991+1655A>G, c.4723A>T (p.Lys1575X) and c.3310-1\_3310delinsAA mutations were the most recurrent, with gene-specific allele frequencies of 49%, 11% and 6%, respectively. Similar to previous studies, most of the mutations are either nonsense, frameshift or splice site mutations. Only two missense variants were identified, of which the pathogenic effect is currently uncertain (p.Ala1566Pro and p.Leu1694Pro) (Supp. Table S2). Overall, 13 novel *CEP290* mutations were identified to cause LCA. The complex allele c.3310-1\_3310delinsAA has a predicted effect on splicing, which was confirmed by cDNA analysis (data not shown). The silent c.1824G>A change affects the last nucleotide of exon 18 and was also predicted to alter splicing (data not shown).

Since *CEP290* mutations may cause a phenotypic spectrum ranging from isolated LCA to more complex disorders, we analysed 13 additional probands suffering from LCA-JS, SLS or CORS. *CEP290* harbored mutations in seven of them (Table 1). Six probands carried known mutations, whereas a novel p.Thr2457AlafsX27 mutation segregated in family LCA-JS-2.

Sequencing of the entire coding region did not reveal a second mutation in LCA-27, while the pathogenic effect of one variant was uncertain in LCA-25 and LCA-26. Subsequent cDNA screening in LCA-25 and LCA-27 was normal, thereby making deep intronic splice site mutations or large exon deletions/duplications very unlikely. No RNA was available for LCA-26.

*CRBI*. Mutations in *CRBI* were found in 15 families with LCA (16%) and 5 families with EORD (Table 1). The LCA chip allowed the identification of a homozygous or compound heterozygous *CRBI* mutation in 15 probands (12 LCA and 3 EORD), and a heterozygous *CRBI* mutation in 3 patients. Sequencing of the whole coding region of *CRBI* in the latter revealed a known and novel mutation, respectively (LCA-29, p.Gln362X and LCA-34, c.4006-1G>T), and a novel unclassified variant (EORD-3, p.Asp491Val) on the second allele (Supp. Table S2). Sequencing of the total coding region identified compound heterozygous mutations in two additional

Deleted: distinct

Deleted: ...In three of them, two heterozygous variants were detected in two genes, respectively. The other one carried a homozygous variant in one gene together with a heterozygous variant in another gene. ... [1]

Deleted: For one patient, t...the mutation ... [2]

Deleted: on the LCA chip

Deleted: (... , *CRBI* p.Glu1330X)... of the LCA chip ... [3]

Deleted: on the LCA chip...dir ... [4]

Deleted: considered ... using LCA chip analysis ... [5]

Deleted: As a second step...complete a ...analysis ...Sanger ... [6]

Deleted: LCA ...all ... in the entire LCA cohort...identified in *CEP290*-related LCA ... [7]

Deleted: , to a lesser extent,

Deleted: ...LCA-25 ... , LCA-2 ... [8]

Deleted: Table 2...that ... [9]

Deleted: : six frameshift mutations, three nonsense mutations, four splice site mutations and the two novel missense variants

Deleted: several ...three SLS, three LCA-JS and one CORS...Five harboured ...in one family, ...with the disease ...(...) ... [10]

Deleted: In two patients, s... (...) and LCA-JS-3)...in two other patients, (...)...three of these patients ... [11]

Deleted: ), a novel mutation (...Table 2...whole ... [12]

proband. In one of them, *CRBI* screening was exceptionally performed without prior LCA chip analysis, given clear clinical indications for a *CRBI*-related phenotype (EORD-2). Indeed, this patient was compound heterozygous for the known p.Cys948Trp mutation, and the novel p.Cys310Tyr variant, which is predicted to disrupt a disulfide bridge (Supp. Table S2). In addition, two sisters with LCA carried two novel frameshift mutations (LCA-41). As previously described, the p.Lys801X and p.Cys948Trp mutations were most frequent, showing gene-specific allele frequencies in the LCA cohort of 27% and 23%, respectively.

**RPE65.** Eight cases with LCA showed mutations in *RPE65* (9%) (Table 1). LCA chip analysis identified a homozygous *RPE65* mutation in LCA-43 and LCA-47, and two compound heterozygous mutations in LCA-49. In addition, a heterozygous mutation was detected in four patients through LCA chip analysis. Sequencing of *RPE65* in these individuals identified three novel mutations and the known p.Phe530LeufsX40 mutation which was not yet present on the LCA chip at the time (LCA-48). Although the evidence for a pathogenic nature of the novel mutation p.Trp331dup is not conclusive, segregation in patient LCA45a, her affected aunt LCA45b and her (healthy) parents sustains a causal role. The two other novel mutations result in a frameshift (LCA-46 and LCA-50). Following sequencing of the total coding region, one additional proband was found to be homozygous for the novel *RPE65* mutation p.Pro181Leu (LCA-44) (Supp. Table S2). Interestingly, segregation analysis of the mutations found in LCA-46 could only confirm segregation of p.Leu341Ser in the mother, suggesting that p.Ser121LeufsX6 occurred *de novo* (paternity confirmed).

**GUCY2D.** Mutations in *GUCY2D* were found in seven probands with LCA (8%) (Table 1). Five of them were identified with *GUCY2D* mutations using the LCA chip. One was homozygous for p.Phe565Ser (LCA-52), while three others carried p.Arg768Trp. One of the latter was homozygous (LCA-53); the other two were compound heterozygous for p.Phe565Ser (LCA-54) and the novel missense change p.Lys866Asn (LCA-55), respectively (Supp. Table S2). In addition, LCA-57 was heterozygous for the p.Pro575Leu variant that was previously identified in the mother of an LCA patient (Koenekoop et al., 2002). However, no second mutation was found. LCA-56 was compound heterozygous for the novel missense changes p.Glu196Val and p.Pro711Leu (Supp. Table S2). In addition, a novel splice site mutation was identified in LCA-51 (c.2577-2A>C).

**AIPL1.** Only two distinct *AIPL1* variants were detected through LCA chip analysis in five LCA patients (5%) (Table 1). The p.Trp278X mutation occurred homozygously in four probands (LCA-58 to LCA-61). In addition, a heterozygous p.Thr114Ile variant was found in proband LCA-62. Direct sequencing of the *AIPL1* gene identified the known variant p.Pro376Ser (missing signal on LCA chip). Segregation analysis in the parents, however, revealed a *cis*-allelic inheritance from the mother. No further mutations were detected following additional sequencing of *AIPL1* in other patients.

**CRX.** LCA chip analysis identified 2 *CRX* missense variants in two LCA patients (Table 1). The p.Tyr142Cys variant was previously described as a mutation (Vallespin et al., 2007a). Stone and colleagues, however, considered this variant as a polymorphism based on the estimate of pathogenic probability and the identification of this variant in a patient with two disease-causing alleles in another LCA gene (Stone, 2007) (LCA-63). The pathogenicity of the second variant p.Val242Met also remains unclear (LCA-64) (Swain et al., 1997; Rivolta et al., 2001; Chen et al., 2002). Given their uncertain pathogenic potential, both variants were discarded as mutations for further calculations.

**RDH12.** Mutation screening of *RDH12* was performed downstream of LCA chip results involving this gene. A heterozygous p.Ala269GlyfsX2 mutation was identified in two probands with EORD. Subsequent sequencing *RDH12* identified an additional novel missense change in both patients, p.Val233Asp (EORD-6) and p.Ser175Leu (EORD-7) respectively (Supp. Table S2). According to UniProt, the Ser175 residue might be a substrate binding site (<http://www.uniprot.org/uniprot/Q96NR8>). A known mutation located in the same codon, p.Ser175Pro, lacks the ability to catalyze the reduction of retinaldehyde to retinol *in vitro* (Lee et al., 2007). In addition, a homozygous p.Ala269GlyfsX2 mutation was identified in patient EORD-8, for which *RDH12* sequencing was performed prior to LCA-chip analysis (upon request).

Deleted: Cys948Trp

Deleted: Table 2

Deleted: two probands (

Deleted: )

Deleted: one patient (

Deleted: )

Deleted: the whole coding region

Deleted: both healthy

Deleted: of LCA45a strongly suggests

Deleted: whole

Deleted: Table 2

Deleted: Patients LCA-47 and LCA-49 were included in a recent Phase I gene therapy clinical trial (Maguire, et al., 2009).

Deleted: mutation

Deleted: was

Deleted: of them

Deleted: the

Deleted: mutation

Deleted: Table 2

Deleted: a

Deleted: not

Deleted: Patient

Deleted: following

Deleted: :

Deleted: Table 2

Deleted: in the *AIPL1* gene

Deleted: with LCA

Deleted: properly segregating

Deleted: in the context

Deleted: analysis

Deleted: direct

Deleted: of the total coding region

Deleted: Table 2

Deleted: exceptionally

*RPGRIP1*. Similarly, screening of *RPGRIP1* was performed in the context of LCA chip analysis. In one LCA patient, a heterozygous mutation was identified. Sequencing of *RPGRIP1*, however, did not identify a second mutation (LCA-65).

Deleted: As for *RDH12*, mutation

Deleted: (1%)

Deleted: the total coding region

*Mutations in multiple LCA genes.* For the assessment of the potential involvement of a second gene in LCA, only variants with significant pathogenic potential were taken into account (see above). Two patients with *CEP290*-related LCA displayed a heterozygous mutation in another LCA gene: LCA-16 was heterozygous for the known p.Arg85Cys mutation in *RPE65*, while LCA-20 carried the common p.Lys801X mutation in *CRB1*.

Deleted: considered

**Identification of potential modifier alleles in the *AH1* gene**

The *AH1* gene was sequenced as a candidate modifier gene in eight patients with *CEP290*-related LCA who presented with mental retardation. Four of them were diagnosed with LCA (LCA-3, LCA-20, LCA-23 and LCA-24); two patients also suffered from NPHP (SLS-2 and SLS-3) and in two other cases, the LCA phenotype was part of a JS diagnosis (CORS-1 and LCA-JS-3). A MTS was absent on brain imaging in two isolated patients with LCA (no data were available for LCA-20, LCA-24, SLS-2 and SLS-3).

A heterozygous novel *AH1* p.Asn811Lys mutation was found in the most severely affected patient CORS-1, out of three patients with the same *CEP290* genotype but different neurological involvement (SLS-2, SLS-3 and CORS-1). Moreover, *AH1* screening in the five remaining patients revealed a second heterozygous missense variant, p.His758Pro, in LCA-3. Conservation and *in silico* predictions for both changes suggest a possible effect on protein structure/function (Supp. Table S2). Interestingly, exonic splicing enhancer (ESE) predictions point to a change in ESEs for both variants (data not shown). Moreover, both changes are located in a conserved WD-40 repeat (<http://www.uniprot.org/uniprot/Q8N157>) and were absent in > 340 Belgian control individuals.

Deleted: 170

In addition, SLS-2 was found to be heterozygous for the known p.Ser1123Phe change. Although it concerns a potentially pathogenic variant that affects a phosphorylation site and is located in a highly conserved region (Dephoure et al., 2008), this change was considered a polymorphism because of its high frequency in the Dutch population and the observation that this change did not segregate in a family with JS (Valente et al., 2006a; Kroes et al., 2008).

**Table 1: Mutations identified in 80 unrelated patients with LCA, using LCA chip analysis and direct sequencing of *CEP290*, *CRB1*, *RPE65*, *AIPL1*, *GUCY2D* and *CRX*.**

Deleted: a series of

Patient	Origin	Par-cons	Segr	Allele 1			Allele 2			Reference
				Intron/exon	Nucleotide change	Amino acid change	Intron/exon	Nucleotide change	Amino acid change	
<i>CEP290</i>										
LCA-1	Belgium	:	X	I26	c.2991+1655A>G*	p.Cys998X*	I26	c.2991+1655A>G*	p.Cys998X*	(den Hollander et al., 2006)
LCA-2	Belgium	:	X	I26	c.2991+1655A>G	p.Cys998X	I26	c.2991+1655A>G	p.Cys998X	(den Hollander et al., 2006)
LCA-3*	Belgium	:	X	I26	c.2991+1655A>G*	p.Cys998X*	E6	c.322C>T	p.Arg108X	(den Hollander et al., 2006)
LCA-4	Belgium	:	NA	I26	c.2991+1655A>G	p.Cys998X	E25	c.2695C>T	p.Gln899X	(den Hollander et al., 2006)
LCA-5	Belgium	:	NA	I26	c.2991+1655A>G	p.Cys998X	E34	c.4393C>T	p.Arg1465X	(den Hollander et al., 2006), (Brancati et al., 2007) (CORS)
LCA-6	Belgium	:	X	I26	c.2991+1655A>G	p.Cys998X	E36	c.4723A>T	p.Lys1575X	(den Hollander et al., 2006), (Brancati et al., 2007; Perrault et al., 2007)
LCA-7 <sup>F</sup>	Belgium	:	NA	I26	c.2991+1655A>G	p.Cys998X	E36	c.4723A>T	p.Lys1575X	(den Hollander et al., 2006), (Brancati et al., 2007; Perrault et al., 2007)
LCA-8	Belgium	:	NA	I26	c.2991+1655A>G	p.Cys998X	E36	c.4723A>T	p.Lys1575X	(den Hollander et al., 2006), (Brancati et al., 2007; Perrault et al., 2007)

Deleted: è

8 Coppieters et al.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Patient	Origin	Par cons	Segr	Allele 1			Allele 2			Reference
				Intron/ exon	Nucleotide change	Amino acid change	Intron/ exon	Nucleotide change	Amino acid change	
										2007)
LCA-9	Belgium	-	X	I26	c.2991+1655A>G	p.Cys998X	E39	c.5344C>T	p.Arg1782X	(den Hollander et al., 2006)
LCA-10	Lithuania	-	X	I26	c.2991+1655A>G	p.Cys998X	E6	c.384_385del	p.Asp128GlnfsX17	(den Hollander et al., 2006)
LCA-11	Belgium	-	X	I26	c.2991+1655A>G	p.Cys998X	E6	c.437del	p.Glu146GlyfsX17	(den Hollander et al., 2006)
LCA-12	The Netherlands	-	NA	I26	c.2991+1655A>G*	p.Cys998X*	E19	c.1859_1862del	p.Arg621IlefsX2	(den Hollander et al., 2006), (Perrault et al., 2007)
LCA-13	Belgium	-	NA	I26	c.2991+1655A>G	p.Cys998X	E29	c.3422dup	p.Leu1141PhefsX5	(den Hollander et al., 2006)
LCA-14	Belgium/Morocco	-	X	I26	c.2991+1655A>G*	p.Cys998X*	E31	c.4001del	p.Thr1334IlefsX2	(den Hollander et al., 2006)
LCA-15	Belgium	-	NA	I26	c.2991+1655A>G	p.Cys998X	E37	c.4962_4963del	p.Glu1656AsnfsX3	(den Hollander et al., 2006), (Perrault et al., 2007)
LCA-16*	Belgium/Greece	-	X	I26	c.2991+1655A>G	p.Cys998X	E40	c.5493del	p.Ala1832ProfsX19	(den Hollander et al., 2006), (Brancati et al., 2007; Frank et al., 2008) (CORS)
LCA-17	Belgium	-	X	I26	c.2991+1655A>G	p.Cys998X	E40	c.5519_5537del	p.Lys1840ArgfsX5	(den Hollander et al., 2006)
LCA-18	Belgium	-	X	I26	c.2991+1655A>G	p.Cys998X	E43	c.5865_5867delins GG	p.Glu1956GlyfsX9	(den Hollander et al., 2006)
LCA-19	Belgium	-	X	I26	c.2991+1655A>G	p.Cys998X	I13	c.1189+1G>A	Donor Splice defect	(den Hollander et al., 2006)
LCA-20*	Belgium	-	NA	I26	c.2991+1655A>G	p.Cys998X	I21	c.2218-2A>C	Acceptor Splice defect	(den Hollander et al., 2006)
LCA-21	Belgium	-	X	I26	c.2991+1655A>G	p.Cys998X	I28-E29	c.3310-1_3310delinsAA	Acceptor splice defect	(den Hollander et al., 2006)
LCA-22	Belgium	-	NA	I26	c.2991+1655A>G	p.Cys998X	I28-E29	c.3310-1_3310delinsAA	Acceptor splice defect	(den Hollander et al., 2006)
LCA-23	Belgium	-	NA	I26	c.2991+1655A>G	p.Cys998X	I28-E29	c.3310-1_3310delinsAA	Acceptor splice defect	(den Hollander et al., 2006)
LCA-24	Belgium	-	NA	E36	c.4723A>T	p.Lys1575X	E36	c.4723A>T	p.Lys1575X	(Perrault et al., 2007)
LCA-25 <sup>F</sup>	Belgium	-	X	E36	c.4723A>T	p.Lys1575X	E35	c.4696G>C	p.Ala1566Pro UV	(Perrault et al., 2007)
LCA-26	Belgium	-	X	E18	c.1824G>A	p.= splice site	E38	c.5081T>C	p.Leu1694Pro UV	
LCA-27	Belgium	-	NA	I26	c.2991+1655A>G	p.Cys998X	?	?	?	(den Hollander et al., 2006)
LS-1	Pakistan	FC	X	E2	c.21G>T	p.Trp7Cys	E2	c.21G>T	p.Trp7Cys	(Valente et al., 2006b) (CORS)
LS-2	Belgium	-	NA	E36	c.4723A>T	p.Lys1575X	E34	c.4393C>T	p.Arg1465X	(Perrault et al., 2007), (Brancati et al., 2007) (CORS)
LS-3	Belgium	-	NA	E36	c.4723A>T	p.Lys1575X	E34	c.4393C>T	p.Arg1465X	(Perrault et al., 2007), (Brancati et al., 2007) (CORS)
CORS-1*	Belgium	SD	NA	E36	c.4723A>T	p.Lys1575X	E34	c.4393C>T	p.Arg1465X	(Perrault et al., 2007), (Brancati et al., 2007) (CORS)
LCA-JS-1	Belgium	-	X	I40	c.5587-1G>C	Acceptor Splice defect	E31	c.3793C>T	p.Gln1265X	(Perrault 2007), (Baala et al., 2007) (ML)
LCA-JS-2 II				E54	c.7366_7369del	p.Thr2457AlafsX27	E54	c.7366_7369del	p.Thr2457AlafsX27	
LCA-JS-2 III	ND	±	X	E54	c.7366_7369del	p.Thr2457AlafsX27	E54	c.7366_7369del	p.Thr2457AlafsX27	
LCA-JS-3	Belgium	-	NA	I28-E29	c.3310-1_3310delinsAA	Acceptor splice defect	E54	c.7341dup	p.Leu2448ThrfsX8	(Sayer et al., 2006)

Deleted: ð

Patient	Origin	Par-cons	Segr	Allele 1			Allele 2			Reference	Deleted: ð
				Intron/exon	Nucleotide change	Amino acid change	Intron/exon	Nucleotide change	Amino acid change		
LCA-28	Belgium	-	NA	E7	c.2401A>T*	p.Lys801X*	E7	c.2401A>T*	p.Lys801X*	(den Hollander et al., 2001)	
LCA-29 (Yzer et al., 2006)	Belgium	-	NA	E7	c.2401A>T*	p.Lys801X*	E5	c.1084C>T	p.Gln362X	(den Hollander et al., 2001) (Yzer et al., 2006)	
LCA-30	Belgium	-	X	E7	c.2401A>T*	p.Lys801X*	E7	c.2290C>T*	p.Arg764Cys*	(den Hollander et al., 2001) (Lotery et al., 2001)	
LCA-31 (Yzer et al., 2006)	Belgium	-	X	E7	c.2401A>T*	p.Lys801X*	E8	c.2688T>A*	p.Cys896X*	(den Hollander et al., 2001) (Hainein et al., 2004)	
LCA-32 (Yzer et al., 2006)	Belgium	-	NA	E7	c.2401A>T*	p.Lys801X*	E8	c.2688T>A*	p.Cys896X*	(den Hollander et al., 2001) (Hainein et al., 2004)	
LCA-33	Belgium	-	NA	E7	c.2401A>T*	p.Lys801X*	E9	c.2843G>A*	p.Cys948Tyr*	(den Hollander et al., 2001) (Lotery et al., 2001)	
LCA-34	Belgium	-	X	E7	c.2401A>T*	p.Lys801X*	I11	c.4006-1G>T	Acceptor splice defect	(den Hollander et al., 2001)	
LCA-35	Belgium	±	NA	E9	c.2843G>A*	p.Cys948Tyr*	E9	c.2843G>A*	p.Cys948Tyr*	(Lotery et al., 2001)	
LCA-36	ND	-	NA	E9	c.2843G>A*	p.Cys948Tyr*	E11	c.3988G>T*	p.Glu1330X*	(Lotery et al., 2001) (LCA chip)	
LCA-37	Belgium	-	X	E9	c.2843G>A*	p.Cys948Tyr*	I8	c.2842+5G>A*	Splice defect*	(Lotery et al., 2001) (den Hollander et al., 1999)	
LCA-38	Belgium	-	X	E9	c.2843G>A*	p.Cys948Tyr*	I8	c.2842+5G>A*	Splice defect*	(Lotery et al., 2001) (den Hollander et al., 1999)	
LCA-39a				E9	c.2843G>A*	p.Cys948Tyr*	I8	c.2842+5G>A*	Splice defect*	(Lotery et al., 2001) (den Hollander et al., 1999)	
LCA-39b	Belgium	-	X				I8	c.2842+5G>A	Splice defect	(Hainein et al., 2004) (den Hollander et al., 1999)	
LCA-40	Belgium	-	NA	I11	c.4005+1G>A*	Splice defect*	I8	c.2842+5G>A*	Splice defect*	(Hainein et al., 2004) (den Hollander et al., 1999)	
LCA-41 II-1	Belgium	-	X	E7	c.2441_2442del	p.Leu814ArgfsX23	E9	c.3713_3716dup	p.Cys1240ProfsX24		Deleted:
LCA-41 II-2	Belgium	-	X	E7	c.2441_2442del	p.Leu814ArgfsX23	E9	c.3713_3716dup	p.Cys1240ProfsX24		Deleted:
LCA-42	ND	±	NA	E11	c.3879G>A*	p.Trp1293X*	E11	c.3879G>A*	p.Trp1293X*	(Hainein et al., 2001)	Deleted:
ORD-1 II-1				E9	c.2843G>A*	p.Cys948Tyr*	E7	c.2401A>T*	p.Lys801X*	(Lotery et al., 2001) (den Hollander et al., 2001)	
ORD-1 II-2	Belgium	-	X				E7	c.2401A>T	p.Lys801X	(Lotery et al., 2001) (den Hollander et al., 2001)	
ORD-2	Belgium		NA	E9	c.2843G>A	p.Cys948Tyr	E4	c.929G>A	p.Cys310Tyr	(Lotery et al., 2001)	
ORD-3	Belgium	-	X	E9	c.2843G>A*	p.Cys948Tyr*	E6	c.1472A>T	p.Asp491Val UV	(Lotery et al., 2001)	
ORD-4	Belgium		NA	E5	c.1084C>T*	p.Gln362X*	E5	c.1084C>T*	p.Gln362X*	(Yzer et al., 2006)	
ORD-5	Belgium	-	NA	E7	c.2290C>T*	p.Arg764Cys*	E7	c.2290C>T*	p.Arg764Cys*	(Lotery et al., 2001)	
<b>RPE65</b>											
LCA-43	Turkey	FC	X	E3	c.131G>A*	p.Arg44Gln*	E3	c.131G>A*	p.Arg44Gln*	(Simovich et al., 2001)	
LCA-44	Turkey	FC	X	E6	c.542C>T	p.Pro181Leu	E6	c.542C>T	p.Pro181Leu		
LCA-45a				E7	c.700C>T*	p.Arg234X*	E9	c.991_993dup	p.Trp331dup	(Marlhens et al., 1997)	
LCA-45b	Belgium	-	X	E9	c.991_993dup	p.Trp331dup	E9	c.991_993dup	p.Trp331dup		
LCA-46	Portugal		X (c.1022T>C)	E10	c.1022T>C*	p.Leu341Ser*	E5	c.361delT	p.Ser121LeufsX6 de novo	(Morimura et al., 1998) (ARRP)	

10 Coppieters et al.

Patient	Origin	Par cons	Segr	Allele 1			Allele 2			Reference
				Intron/exon	Nucleotide change	Amino acid change	Intron/exon	Nucleotide change	Amino acid change	
LCA-47	Belgium	-	X	E14	c.1590del*	p.Phe530LeufsX40*	E14	c.1590del*	p.Phe530LeufsX40*	(Yzer et al., 2006)
LCA-48	Belgium	-	X	E14	c.1590del	p.Phe530LeufsX40	E5	c.370C>T*	p.Arg124X*	(Yzer et al., 2006) <sub>2</sub> (Morimura et al., 1998)
LCA-49	Belgium	-	X	E14	c.1590del*	p.Phe530LeufsX40*	I1	c.11+5G>A*	Splice defect*	(Yzer et al., 2006) <sub>2</sub> (Gu et al., 1997)
LCA-50	Belgium/Russia (mother)	-	X	E9	<b>c.886dupA</b>	<b>p.Arg296LvsfsX7</b>	I1	c.11+5G>A*	Splice defect*	(Gu et al., 1997)
<b>GUCY2D</b>										
LCA-51	Morocco/Belgium	-	NA	E2	c.389del	p.Pro130LeufsX36	<b>I13</b>	<b>c.2577-2A&gt;C</b>	<b>Splice defect</b>	(Perrault et al., 1996)
LCA-52	Turkey	TC	NA	E8	c.1694T>C*	p.Phe565Ser*	E8	c.1694T>C*	p.Phe565Ser*	(Perrault et al., 1996)
LCA-53	Belgium	-	NA	E12	c.2302C>T*	p.Arg768Trp*	E12	c.2302C>T*	p.Arg768Trp*	(Lotery et al., 2000)
LCA-54	Morocco/Belgium	-	X	E12	c.2302C>T*	p.Arg768Trp*	E8	c.1694T>C*	p.Phe565Ser*	(Lotery et al., 2000) <sub>2</sub> (Perrault et al., 1996)
LCA-55	Belgium	-	X	E12	c.2302C>T*	p.Arg768Trp*	<b>E14</b>	<b>c.2598G&gt;C</b>	<b>p.Lvs866Asn</b>	(Lotery et al., 2000)
LCA-56	Belgium/France	-	X	<b>E2</b>	<b>c.587A&gt;T</b>	<b>p.Glu196Val UV</b>	<b>E11</b>	<b>c.2132C&gt;T</b>	<b>p.Pro711Leu UV</b>	
LCA-57	Africa	-	NA	E8	c.1724C>T*	p.Pro575Leu* UV	?	?	?	(Koenekoop et al., 2002)
<b>MIPL1</b>										
LCA-58 (Yzer et al., 2006)	Belgium	-	X	E6	c.834G>A*	p.Trp278X*	E6	c.834G>A	p.Trp278X	(Sohocki et al., 2000a)
LCA-59	Belgium	-	NA	E6	c.834G>A*	p.Trp278X*	E6	c.834G>A*	p.Trp278X*	(Sohocki et al., 2000a)
LCA-60	Belgium	-	NA	E6	c.834G>A*	p.Trp278X*	E6	c.834G>A*	p.Trp278X*	(Sohocki et al., 2000a)
LCA-61	Belgium	-	X	E6	c.834G>A*	p.Trp278X*	E6	c.834G>A*	p.Trp278X*	(Sohocki et al., 2000a)
LCA-62	Africa	-	<i>in cis</i>	E3 E6	c.341C>T* UV c.1126C>T UV	p.Thr114Ile* UV p.Pro376Ser UV	?	?	?	(Sohocki et al., 2000b)
<b>CRY</b>										
LCA-63	Belgium	SC	NA	E4	c.425A>G*	p.Tyr142Cys* UV	?	?	?	(Vallespin et al., 2007a)
LCA-64	Ruanda	-	NA	E3	c.724G>A*	p.Val242Met* UV	?	?	?	(Swain et al., 1997)
<b>RDH12</b>										
CORS-6	Belgium	-	X	E6	c.806_810del*	p.Ala269GlyfsX2*	E8	c.698T>A	p.Val233Asp	(Janecke et al., 2004) <sub>2</sub> <a href="https://www.carverlab.org/carver-mutation-database">https://www.carverlab.org/carver-mutation-database</a>
CORS-7	Belgium	±	X	E6	c.806_810del*	p.Ala269GlyfsX2*	<b>E7</b>	<b>c.524C&gt;T</b>	<b>p.Ser175Leu</b>	(Janecke et al., 2004)
CORS-8	Belgium	-	NA	E6	c.806_810del	p.Ala269GlyfsX2	E6	c.806_810del	p.Ala269GlyfsX2	(Janecke et al., 2004)
<b>TPGRIP1</b>										
LCA-65	Belgium	-	NA	E16	c.2668C>T*	p.Arg890X*	?	?	?	(Gerber et al., 2001)

Deleted: ð

Novel mutations are indicated in bold. \*: patients carrying a heterozygous mutation in an additional gene: LCA-3 (*AH11*, c.2273A>C, p.His758Pro), LCA-16 (*RPE65*, c.253C>T, p.Arg85Cys) (Stone, 2007), LCA-20 (*CRB1*, c.2401A>T, p.Lys801X) (den Hollander et al., 2001) and CORS-1 (*AH11*, c.2433T>G, p.Asn811Lys). \*: identified through LCA chip analysis. <sup>F</sup>: LCA-7 and LCA-25 are distantly related. X: segregation analysis performed and segregation confirmed. NA: no material available of family members. Reference: first publication describing the mutation in patients with LCA or **EORD**. In case of *CEP290*, these references may also refer to papers dealing with other phenotypes (phenotype mentioned between brackets). Seven patients were already described (corresponding reference is indicated in the first column). Abbreviations used: par cons: parental consanguinity; segr: segregation; FC: first cousins; SC: second cousins; TC: third cousins; SD: second degree; ND: no data; UV, unclassified variant; LCA, Leber Congenital Amaurosis; SLS, Senior-Loken syndrome; JS, joubert syndrome; ARRP, autosomal recessive retinitis pigmentosa; CORS, cerebello-oculo-renal syndrome; ML, Meckel-like syndrome.


Deleted: (early-onset) RP

Deleted: CRD, cone-rod dystrophy;

### Clinical findings

Extensive ophthalmological data (best corrected visual acuity [BCVA], refraction, ERG, visual fields, color vision testing, fundus aspect both with white light and autofluorescence imaging and the presence of nystagmus, night blindness, photophobia and additional features) as well as associated manifestations in patients with *CRB1*, *RPE65*, *GUCY2D*, *AIPL1*, *CRX*, *RPGRIP1* and *RDH12* mutations are summarized in detail in [Supp. Table S3](#). In addition, Figure 1 depicts several representative fundi from patients with an established molecular diagnosis. An MTS due to midbrain abnormalities with cerebellar vermis aplasia was demonstrated in five patients with JS-LCA/CORS and *CEP290* mutations (Figure 2).

Special attention was paid to the *CEP290*-related ocular phenotype, since this has been described in only a few LCA studies so far. It appeared that this phenotype displays only limited fundus alterations in the first few years of life. In a small subset of patients, no fundus abnormalities were obvious early on, while in the majority a marbled fundus and/or salt and pepper aspect was seen during the first decade. This aspect further evolved from young adulthood into progressive outer retinal atrophy in the midperiphery with relative sparing of the central macula. Abnormalities of the central macula were absent in our patient cohort, despite the impression that *CEP290*-related disease is probably of a cone-rod type (based on ERG findings and the occurrence of photophobia). Of note is the presence of a hyperautofluorescent ring around the central macula on AF imaging, observed in four patients starting from the age of six (LCA-2, LCA-3, LCA-7 and LCA-25). Mild intraretinal spicular pigment migration occurred in three patients at an age between 7 and 33 years old (LCA-JS-1, LCA-6 and LCA-7). This aspect became even more pronounced at the age of 49 in patient LCA-7, where a predominant spicular pigmentation was mixed with less frequent intraretinal pigment migration with a nummular aspect. Visual acuity of this group was mostly limited to light perception. In the few patients with better preserved central vision, basic color vision was present and visual fields varied from severely concentrically constricted (LCA-8) to sparing of the central 30° at an age of 49 (LCA-7) ([Supp. Table S3](#)).



**Figure 2: Magnetic resonance imaging (MRI) showing characteristic molar tooth sign (MTS) in five patients with Joubert syndrome/cerebello-oculo-renal syndrome due to mutations in *CEP290* (all are axial sections through midbrain).**

Images organized from left to right; arrows indicate MTS of midbrain present in all due to midbrain malformation with hypoplastic cerebellar vermis and midline cleft (all images are T1 weighted except for panel D, which is T2 weighted). A) CORS-1 at age 5 years; B) LCA-JS-1 at age 7 years; C) LCA-JS-2 II-1 at age 14 years; D) LCA-JS-2 II-2 at age 17 years and E) LCA-JS-3 at age 2 years.

Deleted: ¶

Deleted: ¶

Deleted: Supplementary

Deleted: 1


Deleted: subtype

Deleted: early

Deleted: Supplementary

Deleted: 1

Deleted: C



**Figure 1: Clinical characteristics of eight LCA patients with an established molecular diagnosis, illustrating characteristic phenotypic features associated with different genotypes.**

**CEP290**, **A & B**: Early and later stage phenotype in right eye (RE) in LCA-3 at age 3 and 18 years respectively; note marbled aspect of midperiphery at age 3, evolving towards atrophy later; macula stays well-preserved throughout evolution. **C & D**: Fundus and autofluorescence (AF) image of RE of LCA-25 at age eight years; note concentric hyperautofluorescent ring around macula suggesting a watershed zone between better and more affected retina with probably central area the better; midperipheral retina shows diffuse mottled hyperautofluorescence suggesting widespread outer retinal disease. **E & F**: Fundus image of RE and infrared image of left eye (LE) of LCA-7 at age 33 and 49 years respectively; note pigment epithelium alterations in the mid- and far periphery of retina but no intraretinal pigmentation, and with fair preservation of macular area at age 33; at age 49 macula is still fairly well-preserved, but outer retinal atrophy and spicular intraretinal pigmentation is now prominent. **CRB1**, **G**: Fundus of RE of LCA-39a at age 16, showing typical yellowish discoloration of atrophic macula, surrounded by nummular type of intraretinal pigmentation; mild pseudopapilledema and preapillary paravascular fibrosis also visible, as is peripheral greyish hue of outer retinal atrophy with fine white flecks and nummular pigmentation. **GUCY2D**, **H & I**: Fundus and AF image of RE of LCA-55 at age 9 years; fundus is essentially quite normal with only mild pigment epithelium alterations in the retinal periphery; however, AF image shows hyperautofluorescence in central macular area. **RPE65**, **J**: Fundus of LE of LCA-49 at age 10 who subsequently underwent gene therapy with AAV2-hRPE65v2 in RE (Maguire et al. 2009); apart from some discrete pigment epithelium alterations fundus is essentially normal; autofluorescence imaging could not be obtained due to lack of lipofuscin accumulation in retinal pigment epithelium (RPE) typical of this type of LCA. **AIP1L1**, **K & L**: Fundus and AF image of RE of LCA-61 at age 19 years; central macular atrophy with yellowish hue is surrounded by area of better preserved peripheral macula; outer retinal atrophy with spicular intraretinal pigmentation visible in periphery; AF shows black area of atrophic central macula, but is typically not surrounded by hyperautofluorescent ring. **RDH12**, **M & N**: Fundus of EORD-7 at age 5 and 19 years respectively; note mild macular RPE changes which become more prominent with

Deleted: ¶

Deleted: (Images organized clockwise from top left),¶

Deleted: phenotype

Deleted: ¶

Deleted: female patient

Deleted: e

Deleted: ¶

Deleted: C

Deleted: male patient

Deleted: ¶

Deleted: male patient

Deleted: ¶

Deleted: phenotype

Deleted: ¶

Deleted: female patient

Deleted: intraretinal

Deleted: ¶

Deleted: phenotype

Deleted: ¶

Deleted: male patient

Deleted: ¶

Deleted: phenotype

Deleted: ¶

Deleted: male patient

Deleted: he

Deleted: at same age

Deleted: ¶

Deleted: phenotype

Deleted: ¶

Deleted: female patient

Deleted: ¶

Deleted: phenotype

Deleted: ¶

Deleted: male patient

age; mild predominantly spicular intraretinal pigmentation also increases with age; however, preservation of patches of normal peripheral retina are most striking feature; these patches remain over time.

DISCUSSION

**Genotypes of the Belgian LCA population**

In a cohort of 91 unrelated LCA patients, mainly originating from Belgium, a total of 61 different mutations (including 9 UVs) were found in 7 genes. **Homozygous or compound heterozygous mutations were detected in 65% (59/91) of probands, whereas only one heterozygous mutation could be identified in 4% (4/91) of probands.** In addition to isolated LCA, this study also identified mutations in eight probands with EORD and seven probands with syndromic LCA (SLS, LCA-JS and CORS) (Table 1).

LCA chip analysis proved to be a powerful initial tool as mutations were found in 41% (37/91) of patients with LCA. Subsequent sequencing of 6 genes (*CEP290*, *CRB1*, *RPE65*, *GUCY2D*, *AIPL1* and *CRX*) enabled us to identify mutations in an additional 28% of cases. **Of note, the majority of mutations found in the latter probands are now included in the LCA chip, increasing its detection rate to 65% if our cohort would have been analyzed using the latest version (v8, 641 variants).**

Segregation of disease alleles was demonstrated in 41 out of 43 families available, with two exceptions. The first one is LCA-62, in which the *AIPL1* variants p.Thr114Ile and p.Pro376Ser were located in cis on the maternal chromosome. This finding challenges a previous study proposing this genotype as causal in an LCA patient (Sohocki et al., 2000b). In the second case, only one of two mutations identified in LCA-46 was found in the mother but not in father, suggesting that the other mutation arose de novo (p.Ser121LeufsX6, non-paternity excluded) (Table 1). Of note, two different mutations in *CEP290* were identified in CORS-1, originating from a consanguineous marriage, which illustrates that assuming homozygosity in offspring from a consanguineous mating can be a potential pitfall for the identification of the causal defect (Table 1).

Our data demonstrate a key role for *CEP290* in the Belgian LCA population, as *CEP290* mutations were identified in 27 probands (30%). Although the prevalence of *CEP290* mutations is not this high worldwide (Simonelli et al., 2007; Vallespin et al., 2007b; Seong et al., 2008; Li et al., 2009; Sundaresan et al., 2009), this study corroborates the importance of *CEP290* in the Northwestern European population (den Hollander et al., 2006; Perrault et al., 2007). The second most frequently mutated gene in our LCA population was *CRB1* (16%), followed by *RPE65* (9%), *GUCY2D* (8%) and *AIPL1* (5%), which is in agreement with previous data (den Hollander et al., 2008). **The *RPGRIPI* gene – in this study only investigated with the LCA chip – accounted for less than 1% of the LCA population.**

In total, 30 novel mutations/variants were identified in this study (Table 1, Supp. Table S2). Interestingly, 5 out of 16 novel mutations in *CEP290* are located nearby known changes: c.384\_385del (c.384\_387del, c.381\_382delinsT) (Baala et al., 2007; Perrault et al., 2007), c.2218-2A>C (c.2218-4\_2222del and c.2218-15\_2220del) (Sayer et al., 2006; Stone, 2007), c.3310-1\_3310delinsAA (c.3310-1G>C) (Tory et al., 2007), c.5519\_5537del (c.5515\_5518del) (Sayer et al., 2006) and c.5865\_5867delinsGG (c.5866G>T) (den Hollander et al., 2006). A similar observation was made for *RDH12*, in which the novel mutation p.Ser175Leu affects the same codon as the known mutation p.Ser175Pro (Perrault et al., 2004). Overall, these regions/codons might be more prone to mutational events.

For several genes, a limited number of recurrent mutations made up the majority of mutated alleles. This was certainly the case for *CEP290*, in which c.2991+1655A>G was found in 89% of all LCA patients with *CEP290*-related pathology. Together with p.Lys1575X and c.3310-1\_3310delinsAA, a significant fraction of mutated alleles was identified in the LCA population (35/53 alleles). So far, p.Lys1575X has only been found in patients originating from northern France (Perrault et al., 2007) or Belgium (Brancati et al., 2007). This potential founder effect is supported by our study, since all patients who carry p.Lys1575X live in Flanders (northern part of Belgium). A similar regional prevalence was seen for p.Alal832ProfsX19, which was inherited from the Greek father of LCA-16. The same mutation occurred in an Italian patient with CORS (Brancati et al., 2007) and in two consanguineous families of Kosovar-Albanian and Kosovar origin with MKS, sharing a common haplotype (Frank et al., 2008). For the other genes, the following mutations presented with a gene-specific allele-frequency of at least 20% in the LCA population: p.Lys801X (*CRB1*, 27%), p.Cys948Tyr (*CRB1*, 23%), p.Phe530LeufsX40

Deleted: nine ...seven ..., 26 of which were novel [13]

Deleted: .

Deleted: Mutations were identified in 69% (63/91) of probands, with an established diagnosis - two mutations found - in 65% (59/91). .....five of which were novel mutations [14]

Deleted: 43...9...6...all patients of this study [15]

Deleted: could be...in which testing was possible...the ... of two prof [16]

Deleted: one concerns patient

Deleted: missense ...in *AIPL1* describing [17]

Deleted: the observation of Sohocki and colleagues, who previously described

Deleted: these ...changes ...mutations with LCA ...both [18]

Deleted: patient

Deleted: compound heterozygous...an individual ...all ...CORS-1, [19]

Deleted: the ...gene ...in *CEP290* [20]

Deleted: ... and *RPGRIPI* (1% [21]

Deleted: through... analysis ...The two variants identified in *CRX* had an uncertain pathogenic potential and were therefore not included in these calculations. [22]

Deleted: 31 ...variants/...patients with LCA, EORD, SLS, LCA-JS or CORS.... Segregation and thorough bioinformatic evaluation allowed interpretation of these variants ...Table 2 [23]

Deleted: the

Deleted: the ...in [24]

Deleted: which

Deleted: showing

Deleted: was demonstrated

(*RPE65*, 25%), p.Arg768Trp (*GUCY2D*, 31%), p.Phe565Ser (*GUCY2D*, 23%) and p.Trp278X (*AIPL1*, 89%). The presence of all but one of these mutations on the LCA chip significantly contributed to its high detection rate.

In six LCA patients, only one mutation was found after sequencing of the gene apparently involved following chip testing. Notably, we might have failed to detect deep intronic and regulatory mutations or multi-exon deletions, as [were](#) recently demonstrated in *CEP290* (Travaglini et al., 2009). In addition, it cannot be excluded that the phenotype is caused by mutations in a different gene, as [was](#) the case for LCA-20. Furthermore, new mutations in the other known genes cannot be [ruled out](#) here. Their contribution is expected to be limited however, taking into account the high detection rate obtained using the current strategy. Finally, these patients may carry mutations in as yet unknown genes.

#### Phenotypes of the Belgian LCA population

In addition, the phenotypes of patients with a molecular diagnosis were extensively studied. For all genes, nystagmus and hypermetropia were recurrent features. The oculodigital sign (plus [enophthalmos](#)) was often seen in all but *RPE65*-related LCA patients. A relatively higher incidence of both keratoconus and cataract was seen in the *CRB1*-related group, which may reflect secondary effects of a more severe retinal dystrophy compared to other genes. Indeed, several retinal abnormalities such as macular atrophy and intraretinal pigment migration already became apparent in the first decade of life in patients with *CRB1*-related disease, [being](#) earlier than generally seen for the other genes. In addition, a yellowish discoloration of the central macula was often observed. However, this feature is not entirely gene-specific, since it also occurred in a patient carrying *RDH12* mutations (EORD-7). This feature may be due to more severe outer retinal atrophy in the macula in *CRB1*- and *RDH12*-related disease, which may cause more intense scleral light reflection due to less absorption by the atrophic retinal pigment epithelium, with consequent highlighting of the macular luteal pigment.

The *RPE65*-related phenotype proved to be typically associated with a fundus appearance which is essentially normal during first years and displays only later on fundus alterations which are initially mild. Visual acuity is generally somewhat better than that seen in *CRB1*-related LCA. However, it seems to be the relatively slow evolution of the phenotype which makes it particularly suitable for therapeutic intervention (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008). For two patients from our cohort ([LCA-47 and LCA-49](#)), *RPE65* gene-replacement therapy resulted in better visual function (Maguire et al., 2009). In addition, two patients with *RPE65* mutations reported a period of increased visual function, possibly reflecting postnatal physiological cone maturation (LCA-44 and LCA-47) (Koenekoop et al., 2007). Hanein et al. classified both *CRB1*- and *RPE65*-related LCA as rod-cone dystrophies because of a predominant occurrence of night blindness (Hanein et al., 2004). All *RPE65*-related phenotypes in this study correspond to this classification. In the *CRB1*-group, however, six patients with LCA and two with EORD also suffered from photophobia, [even](#) before the onset of night blindness in EORD-3.

Similarly, the *GUCY2D*-related phenotype was found to have only limited fundus abnormalities. Although this phenotype was previously categorized as cone-rod dystrophy, one patient in our cohort had severe night blindness before photophobia became apparent (LCA-54).

In the patients with *AIPL1* mutations, an RP-like phenotype emerged by their teenage years at the latest, and a maculopathy with (partial) outer retinal atrophy was typically present in the majority of cases (Dharmaraj et al., 2004).

A unique feature of *RDH12*-related early-onset dystrophy was the occurrence of areas with complete preservation of the chorioretina in the retinal periphery, alternating with regions of total atrophy (EORD-7).

Notably, our study is one of the first reporting on the ocular phenotype of a larger group of LCA patients with *CEP290* mutations ([Supp. Table S3](#)). In keeping with previously reported findings (Perrault et al., 2007), it appeared to be that of a severe cone-rod type retinal dystrophy. Visual acuity was mostly limited to light perception, as recently described (Walia et al., 2010). Interestingly, a limited subset of patients displayed no obvious retinal abnormalities in the first years of life. In general, the fundus contained either small white dots or, more frequently, a marbleized or salt and pepper aspect in the first to second decade. In two patients aged 18 and 49, predominant spicular pigment migration was observed (LCA-6 and LCA-7), in contrast to the reported nummular pigmentation in one patient in the fourth decade (den Hollander et al., 2006). In one patient, nummular pigmentation was [described](#) in the first decade (LCA-10). Interestingly, a more severe phenotype was seen in LCA-20, who carried a heterozygous *CRB1* null allele on top of two mutations in *CEP290*.

Deleted: direct

Deleted: of the total coding region

Deleted: is

Deleted: in this study

Deleted: excluded since a selection of six genes was sequenced

Deleted: consequent

Deleted: which is

Deleted: ¶

Deleted: Supplementary Table 2

Deleted: 1

Deleted: reported

### Extra-ocular features of *CEP290*-related LCA and potential modifier alleles in *AH11*

Several patients with *CEP290*-related retinal dystrophy showed additional systemic features. Two patients with isolated LCA had several symptoms suggestive of renal dysfunction (LCA-3 and LCA-23, [Supp. Table S3](#)). LCA-3 suffered from growth retardation, polydipsia, enuresis nocturna and diurnal incontinence. Kidney US at the age of seven, however, was normal. In LCA-23, kidney US at the age of three revealed increased echogenicity and kidneys without clear cortico-medullary differentiation. Despite this observation, no clinical nephrological manifestations were present at the age of 17. Since the age of onset of end-stage renal disease caused by *CEP290* mutations may exceed the age of 20 (Helou et al., 2007; Tory et al., 2007), a close nephrological follow-up of these patients is required. Interestingly, both of these patients carry the recurrent c.2991+1655A>G mutation, which so far has only been reported in LCA patients without any other associated pathology. Of note, kidney US was available for only a subset of patients, and in general performed very early in life, when developing kidney disease might be difficult to detect.

In addition, four patients suffered from recurrent otitis media (OM) (LCA-5, SLS-1, SLS-3 and CORS-1, [Supplementary Table 2](#)). Although this is common in childhood, it is worth mentioning that it is also a clinical manifestation often seen in primary ciliary dyskinesia (PCD), a genetically heterogeneous disorder of motile cilia (Leigh et al., 2009). In a few cases, PCD with OM was associated with X-linked RP, caused by mutations in *RPGR* (Shu et al., 2007). Notably, *RPGR* is a centrosomal protein that interacts with *CEP290* (Chang et al., 2006). Moreover, loss-of-function experiments of *CEP290* in zebrafish caused developmental abnormalities of the otic cavity (Sayer et al., 2006).

Strikingly, 33% of patients with *CEP290*-related isolated LCA presented with mental retardation and/or autism, in contrast to only 8% of patients with mutations in the other genes. Subtle brain abnormalities such as broadened lateral ventricles were seen on MRI in some patients. Of note, brain imaging was not available for a subset of patients. Additional neurological manifestations included movement abnormalities (LCA-21), and dyspraxia and balance/coordination problems (LCA-18), the latter of which was also evident in two patients with syndromic *CEP290*-related LCA (SLS-2 and CORS-1) ([Supp. Table S3](#)).

Taken together, these extra-ocular manifestations fit well into the broad clinical spectrum of *CEP290* mutations, varying from isolated LCA to the lethal MKS. In addition, the *CEP290* allelic spectrum is highly complex. Mutations associated with isolated LCA in this study were previously reported in other ciliopathies (Table 1), albeit always in compound heterozygosity with a different mutation in the distinct phenotypes. Moreover, identical *CEP290* genotypes can display interfamilial variable expressivity and intrafamilial variation of the neurological phenotype was observed in several families with *CEP290*-related pathology (Coppieters et al., 2010). The complexity of *CEP290*-related disease is further illustrated by two cases from this study.

The first one is SLS-1, homozygous for p.Trp7Cys. Valente and coworkers identified the same mutation in patient with CORS, also of Pakistani origin (COR22, II:1). Despite a similar ocular and renal phenotype, both patients significantly differ in their neurological phenotype. A second and even more pronounced example is the variability in both nephrological and neurological involvement in three unrelated patients with the same p.Lys1575X/p.Arg1465X genotype (SLS-2, SLS-3 and CORS-1). Patients SLS-3 and CORS-1 displayed a similar clinical course of renal disease, with renal failure at the age of 16 and 14 years, respectively. In contrast, renal insufficiency in patient SLS-2 was not substantiated until the age of 30 ([Supp. Table S3](#)). Neurological signs of these three patients ranged from a mild mental handicap (SLS-2) over severe autism in combination with moderate mental retardation (SLS-3) to severe mental retardation associated with ataxia and a MTS (CORS-1). An MRI was not available for the other two patients, however.

The *AH11* gene was screened as a candidate modifier gene in these three patients. Strikingly, CORS-1, with the most severe nephrologic and neurologic phenotype, carries a heterozygous novel p.Asn811Lys mutation in *AH11*, which was absent in the two other patients. Upon screening of *AH11* in five additional patients with *CEP290*-related disease and neurological involvement, a novel missense variant, p.His758Pro, was identified in LCA-3. Mutations in *AH11* encoding Joubertin are responsible for JS, with retinal involvement in 75% and renal involvement in less than 10% of all *AH11*-associated patients (Kroes et al., 2008). Interestingly, both p.Asn811Lys and p.His758Pro affect conserved residues and are located in the predicted WD40-repeat, a domain conserved across all eukaryotes, mediating functions such as vesicular trafficking (Li and Roberts, 2001). Since *AH11* and *CEP290* appear to be in the same pathway through their interaction with rab8a, mutations in one of both genes

Deleted: Supplementary Table 2

Deleted: 1

Deleted: Patient

Deleted: s

Deleted: patient

Deleted: are

Deleted: limited number

Deleted: 1

Deleted: of which

Deleted: Supplementary Table 2

Deleted: 1

Deleted: occurred

Deleted: ¶

Deleted: who suffers from SLS and is

Deleted: the missense mutation

Deleted: a Pakistani boy

Deleted: involvement

Deleted: Diagnosis of renal disease in both patients was based on kidney US (hyperdensity) and blood tests, and was established at the age of 13 and 6 years, respectively. SLS-3 receives peritoneal dialysis since the age of 17, and is awaiting kidney transplantation. CORS-1 deceased at an age of 16 as a consequence of renal failure.

Deleted: detected

Deleted: Supplementary Table 2

Deleted: , following complaints of nausea and weight loss

Deleted: Haemodialysis and subsequent peritoneal dialysis started at the age of 34 and the patient received kidney transplant six months later.

Deleted: The n

Deleted: n

Deleted: on MRI

Deleted: other

Deleted: that encodes

Deleted: Most of the mutations are null alleles with a few missense mutations mainly clustering within the predicted WD40-repeat, a domain conserved across all eukaryotes, which mediates functions such as vesicular trafficking (Li and Roberts, 2001).

Deleted: this domain and affect conserved residues

may modify a phenotype caused by the other (Kim et al., 2008; Tsang et al., 2008; Hsiao et al., 2009). Tory and colleagues already suggested a similar potential epistatic effect of *CEP290* and *AH11* mutations on phenotypes related to *NPHP1*, encoding another interactor of AH11 (Tory et al., 2007; Eley et al., 2008). Strikingly, one of the *AH11* variants they described as a potential modifier for neurological involvement in patients with *NPHP1* mutations, p.Arg830Trp, was recently identified as a modifier allele for retinal degeneration in patients with *NPHP1*, independent of a primary *NPHP1* mutation (Louie et al., 2010). Of note, four out of seven patients in the study from Tory and coworkers carrying p.Arg830Trp displayed visual impairment, with one blind individual (Tory et al., 2007). The p.Arg830Trp variant might affect AH11 complex stability/formation (Louie et al., 2010). The variants identified here, assumed to represent a neurological modifier in patients with LCA, might disrupt interactions with other proteins, thereby influencing AH11 function in other organ systems.

Overall, a molecular diagnosis of *CEP290* mutations might have considerable consequences towards the clinical prognosis of an individual. Given the potential involvement of ciliary modifiers and the presence of cilia throughout the whole body, the development of various additional clinical manifestations should be taken into account. As for LCA, both children and (young) adults should have a long-term close clinical neurological and nephrological follow-up, since some features have a later onset.

In conclusion, molecular testing identified mutations in 69% of our LCA cohort, with a major involvement of CEP290. Detailed phenotyping of all patients with a molecular diagnosis revealed novel insights, mainly into the *CEP290*-related retinal phenotype, which is well documented for the first time in a larger patient group. The variable age-of-onset of the extra-ocular features emphasizes the importance of long-term clinical follow-up of LCA patients with *CEP290* mutations. Moreover, the identification of potential modifiers of *CEP290*-related disease might contribute to a refined prognosis based on a molecular diagnosis. Finally, our findings fit with previous observations suggesting that the phenotype of ciliopathies is most likely determined by the synergistic effect of all variants occurring in the ciliary proteome.

Deleted: probably

Deleted: s

Deleted: that are

Deleted: one should be very cautious for

Deleted: that can have a wide variety, reflecting the overall presence of cilia throughout the whole body

Deleted: exhaustive genetic

## REFERENCES

- Baala L, Audollent S, Martinovic J, Ozilou C, Babron MC, Sivanandamoorthy S, Saunier S, Salomon R, Gonzales M, Rattenberry E, Esculpavit C, Toutain A, Moraine C, Parent P, Marcorelles P, Dauge MC, Roume J, Le Merrer M, Meiner V, Meir K, Menez F, Beaufrere AM, Francannet C, Tantau J, Sinico M, Dumez Y, MacDonald F, Munnich A, Lyonnet S, Gubler MC, Genin E, Johnson CA, Vekemans M, Encha-Razavi F, Attie-Bitach T. 2007. Pleiotropic effects of *CEP290* (*NPHP6*) mutations extend to Meckel syndrome. *Am J Hum Genet* 81(1):170-9.
- Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. 2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. *N Engl J Med* 358(21):2231-9.
- Bowne SJ, Sullivan LS, Mortimer SE, Hedstrom L, Zhu J, Spellacy CJ, Gire AI, Hughbanks-Wheaton D, Birch DG, Lewis RA, Heckenlively JR, Daiger SP. 2006. Spectrum and frequency of mutations in *IMPDH1* associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis. *Invest Ophthalmol Vis Sci* 47(1):34-42.
- Brancati F, Barrano G, Silhavy JL, Marsh SE, Travaglini L, Bielas SL, Amorini M, Zablocka D, Kayserili H, Al-Gazali L, Bertini E, Boltshauser E, D'Hooghe M, Fazzi E, Fenerci EY, Hennekam RC, Kiss A, Lees MM, Marco E, Phadke SR, Rigoli L, Romano S, Salpietro CD, Sherr EH, Signorini S, Stromme P, Stuart B, Sztriha L, Viskochil DH, Yuksel A, Dallapiccola B, Valente EM, Gleeson JG. 2007. *CEP290* mutations are frequently identified in the oculo-renal form of Joubert syndrome-related disorders. *Am J Hum Genet* 81(1):104-13.
- Chang B, Khanna H, Hawes N, Jimeno D, He S, Lillo C, Parapuram SK, Cheng H, Scott A, Hurd RE, Sayer JA, Otto EA, Attanasio M, O'Toole JF, Jin G, Shou C, Hildebrandt F, Williams DS, Heckenlively JR, Swaroop A. 2006. In-frame deletion in a novel centrosomal/ciliary protein *CEP290/NPHP6* perturbs its interaction with *RPGR* and results in early-onset retinal degeneration in the rd16 mouse. *Hum Mol Genet* 15(11):1847-57.
- Chen S, Wang QL, Xu S, Liu I, Li LY, Wang Y, Zack DJ. 2002. Functional analysis of cone-rod homeobox (*CRX*) mutations associated with retinal dystrophy. *Hum Mol Genet* 11(8):873-84.
- Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, Windsor EA, Conlon TJ, Sumaroka A, Pang JJ, Roman AJ, Byrne BJ, Jacobson SG. 2009. Human *RPE65* gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. *Hum Gene Ther* 20(9):999-1004.
- Coppieters F, Lefever S, Vandesompele J, Leroy BP, De Baere E. 2010. *CEP290*, a gene with many faces: mutation overview and presentation of *CEP290*base. [Under review](#).
- den Hollander AI, Heckenlively JR, van den Born LI, de Kok YJ, van der Velde-Visser SD, Kellner U, Jurkies B, van Schooneveld MJ, Blankenagel A, Rohrschneider K, Wissinger B, Cruysberg JR, Deutman AF, Brunner HG, Apfelstedt-Sylla E, Hoyng CB, Cremers FP. 2001. Leber congenital amaurosis and retinitis pigmentosa with Coats-

Deleted: Submitted

- like exudative vasculopathy are associated with mutations in the crumbs homologue 1 (CRB1) gene. *Am J Hum Genet* 69(1):198-203.
- den Hollander AI, Koenekoop RK, Mohamed MD, Arts HH, Boldt K, Towns KV, Sedmak T, Beer M, Nagel-Wolfrum K, McKibbin M, Dharmaraj S, Lopez I, Iving L, Williams GA, Springell K, Woods CG, Jafri H, Rashid Y, Strom TM, van der Zwaag B, Gosens I, Kersten FF, van Wijk E, Veltman JA, Zonneveld MN, van Beersum SE, Maumenee IH, Wolfrum U, Cheetham ME, Ueffing M, Cremers FP, Inglehearn CF, Roepman R. 2007. Mutations in LCA5, encoding the ciliary protein lebercilin, cause Leber congenital amaurosis. *Nat Genet* 39(7):889-95.
- den Hollander AI, Koenekoop RK, Yzer S, Lopez I, Arends ML, Voesenek KE, Zonneveld MN, Strom TM, Meitinger T, Brunner HG, Hoyng CB, van den Born LI, Rohrschneider K, Cremers FP. 2006. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. *Am J Hum Genet* 79(3):556-61.
- den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. 2008. Leber congenital amaurosis: genes, proteins and disease mechanisms. *Prog Retin Eye Res* 27(4):391-419.
- den Hollander AI, ten Brink JB, de Kok YJ, van Soest S, van den Born LI, van Driel MA, van de Pol DJ, Payne AM, Bhattacharya SS, Kellner U, Hoyng CB, Westerveld A, Brunner HG, Bleeker-Wagemakers EM, Deutman AF, Heckenlively JR, Cremers FP, Bergen AA. 1999. Mutations in a human homologue of *Drosophila* crumbs cause retinitis pigmentosa (RP12). *Nat Genet* 23(2):217-21.
- Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP. 2008. A quantitative atlas of mitotic phosphorylation. *Proc Natl Acad Sci U S A* 105(31):10762-7.
- Dharmaraj S, Leroy BP, Sohocki MM, Koenekoop RK, Perrault I, Anwar K, Khaliq S, Devi RS, Birch DG, De Pool E, Izquierdo N, Van Maldergem L, Ismail M, Payne AM, Holder GE, Bhattacharya SS, Bird AC, Kaplan J, Maumenee IH. 2004. The phenotype of Leber congenital amaurosis in patients with AIPL1 mutations. *Arch Ophthalmol* 122(7):1029-37.
- Dryja TP, Adams SM, Grimsby JL, McGee TL, Hong DH, Li T, Andreasson S, Berson EL. 2001. Null RPGRIP1 alleles in patients with Leber congenital amaurosis. *Am J Hum Genet* 68(5):1295-8.
- Eley L, Gabrielides C, Adams M, Johnson CA, Hildebrandt F, Sayer JA. 2008. Joubertin localizes to collecting ducts and interacts with nephrocystin-1. *Kidney Int* 74(9):1139-49.
- Frank V, den Hollander AI, Bruchle NO, Zonneveld MN, Nurnberg G, Becker C, Du Bois G, Kendziorra H, Roosing S, Senderek J, Nurnberg P, Cremers FP, Zerres K, Bergmann C. 2008. Mutations of the CEP290 gene encoding a centrosomal protein cause Meckel-Gruber syndrome. *Hum Mutat* 29(1):45-52.
- Freund CL, Wang QL, Chen S, Muskat BL, Wiles CD, Sheffield VC, Jacobson SG, McInnes RR, Zack DJ, Stone EM. 1998. De novo mutations in the CRX homeobox gene associated with Leber congenital amaurosis. *Nat Genet* 18(4):311-2.
- Friedman JS, Chang B, Kannabiran C, Chakarova C, Singh HP, Jalali S, Hawes NL, Branham K, Othman M, Filippova E, Thompson DA, Webster AR, Andreasson S, Jacobson SG, Bhattacharya SS, Heckenlively JR, Swaroop A. 2006. Premature truncation of a novel protein, RD3, exhibiting subnuclear localization is associated with retinal degeneration. *Am J Hum Genet* 79(6):1059-70.
- Gerber S, Perrault I, Hanein S, Barbet F, Ducrocq D, Ghazi I, Martin-Coignard D, Leowski C, Homfray T, Dufier JL, Munnich A, Kaplan J, Rozet JM. 2001. Complete exon-intron structure of the RPGR-interacting protein (RPGRIP1) gene allows the identification of mutations underlying Leber congenital amaurosis. *Eur J Hum Genet* 9(8):561-71.
- Gu SM, Thompson DA, Srikumari CR, Lorenz B, Finckh U, Nicoletti A, Murthy KR, Rathmann M, Kumaramanickavel G, Denton MJ, Gal A. 1997. Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy. *Nat Genet* 17(2):194-7.
- Hagstrom SA, North MA, Nishina PL, Berson EL, Dryja TP. 1998. Recessive mutations in the gene encoding the tubby-like protein TULP1 in patients with retinitis pigmentosa. *Nat Genet* 18(2):174-6.
- Hanein S, Perrault I, Gerber S, Tanguy G, Barbet F, Ducrocq D, Calvas P, Dollfus H, Hamel C, Lopponen T, Munier F, Santos L, Shalev S, Zafeiriou D, Dufier JL, Munnich A, Rozet JM, Kaplan J. 2004. Leber congenital amaurosis: comprehensive survey of the genetic heterogeneity, refinement of the clinical definition, and genotype-phenotype correlations as a strategy for molecular diagnosis. *Hum Mutat* 23(4):306-17.
- Hanein S, Perrault I, Gerber S, Tanguy G, Rozet JM, Kaplan J. 2006. Leber congenital amaurosis: survey of the genetic heterogeneity, refinement of the clinical definition and phenotype-genotype correlations as a strategy for molecular diagnosis. *Clinical and molecular survey in LCA. Adv Exp Med Biol* 572:15-20.
- Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon TJ, Boye SL, Flotte TR, Byrne BJ, Jacobson SG. 2008. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. *Hum Gene Ther* 19(10):979-90.
- Helou J, Otto EA, Attanasio M, Allen SJ, Parisi MA, Glass I, Utsch B, Hashmi S, Fazzi E, Omran H, O'Toole JF, Sayer JA, Hildebrandt F. 2007. Mutation analysis of NPHP6/CEP290 in patients with Joubert syndrome and Senior-Loken syndrome. *J Med Genet* 44(10):657-63.
- Henderson RH, Wasele N, Searle R, van der Spuy J, Russell-Eggitt I, Bhattacharya SS, Thompson DA, Holder GE, Cheetham ME, Webster AR, Moore AT. 2007. An assessment of the apex microarray technology in genotyping patients with Leber congenital amaurosis and early-onset severe retinal dystrophy. *Invest Ophthalmol Vis Sci* 48(12):5684-9.
- Hsiao YC, Tong ZJ, Westfall JE, Ault JG, Page-McCaw PS, Ferland RJ. 2009. Ahi1, whose human ortholog is mutated in Joubert syndrome, is required for Rab8a localization, ciliogenesis and vesicle trafficking. *Hum Mol Genet* 18(20):3926-41.

- 1  
2  
3 Janecke AR, Thompson DA, Utermann G, Becker C, Hubner CA, Schmid E, McHenry CL, Nair AR, Ruschendorf F, Heckenlively J, Wissinger B, Nurnberg P, Gal A. 2004. Mutations in RDH12 encoding a photoreceptor cell retinol dehydrogenase cause childhood-onset severe retinal dystrophy. *Nat Genet* 36(8):850-4.
- 4  
5 Keen TJ, Mohamed MD, McKibbin M, Rashid Y, Jafri H, Maumenee IH, Inglehearn CF. 2003. Identification of a locus (LCA9) for Leber's congenital amaurosis on chromosome 1p36. *Eur J Hum Genet* 11(5):420-3.
- 6  
7 Khanna H, Davis EE, Murga-Zamalloa CA, Estrada-Cuzcano A, Lopez I, den Hollander AI, Zonneveld MN, Othman MI, Waseem N, Chakarova CF, Maubaret C, Diaz-Font A, Macdonald I, Muzny DM, Wheeler DA, Morgan M, Lewis LR, Logan CV, Tan PL, Beer MA, Inglehearn CF, Lewis RA, Jacobson SG, Bergmann C, Beales PL, Attie-Bitach T, Johnson CA, Otto EA, Bhattacharya SS, Hildebrandt F, Gibbs RA, Koenekoop RK, Swaroop A, Katsanis N. 2009. A common allele in RPGRIP1L is a modifier of retinal degeneration in ciliopathies. *Nat Genet*.
- 8  
9 Kim J, Krishnaswami SR, Gleeson JG. 2008. CEP290 interacts with the centriolar satellite component PCM-1 and is required for Rab8 localization to the primary cilium. *Hum Mol Genet* 17(23):3796-805.
- 10  
11 Koenekoop RK, Fishman GA, Iannaccone A, Ezzeldin H, Ciccarelli ML, Baldi A, Sunness JS, Lotery AJ, Jablonski MM, Pittler SJ, Maumenee I. 2002. Electroretinographic abnormalities in parents of patients with Leber congenital amaurosis who have heterozygous GUCY2D mutations. *Arch Ophthalmol* 120(10):1325-30.
- 12  
13 Koenekoop RK, Lopez I, den Hollander AI, Allikmets R, Cremers FP. 2007. Genetic testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutions. *Clin Experiment Ophthalmol* 35(5):473-85.
- 14  
15 Kroes HY, van Zon PH, Fransen van de Putte D, Nelen MR, Nievelstein RJ, Wittebol-Post D, van Nieuwenhuizen O, Mancini GM, van der Knaap MS, Kwee ML, Maas SM, Cobben JM, De Nef JE, Lindhout D, Sinke RJ. 2008. DNA analysis of AHI1, NPHP1 and CYCLIN D1 in Joubert syndrome patients from the Netherlands. *Eur J Med Genet* 51(1):24-34.
- 16  
17 Lee SA, Belyaeva OV, Popov IK, Kedishvili NY. 2007. Overproduction of bioactive retinoic acid in cells expressing disease-associated mutants of retinol dehydrogenase 12. *J Biol Chem* 282(49):35621-8.
- 18  
19 Leigh MW, Pittman JE, Carson JL, Ferkol TW, Dell SD, Davis SD, Knowles MR, Zariwala MA. 2009. Clinical and genetic aspects of primary ciliary dyskinesia/Kartagener syndrome. *Genet Med* 11(7):473-87.
- 20  
21 Leitch CC, Zaghoul NA, Davis EE, Stoetzel C, Diaz-Font A, Rix S, Al-Fadhel M, Lewis RA, Eyaid W, Banin E, Dollfus H, Beales PL, Badano JL, Katsanis N. 2008. Hypomorphic mutations in syndromic encephalocele genes are associated with Bardet-Biedl syndrome. *Nat Genet* 40(4):443-8.
- 22  
23 Li D, Roberts R. 2001. WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. *Cell Mol Life Sci* 58(14):2085-97.
- 24  
25 Li Y, Wang H, Peng J, Gibbs RA, Lewis RA, Lupski JR, Mardon G, Chen R. 2009. Mutation survey of known LCA genes and loci in the Saudi Arabian population. *Invest Ophthalmol Vis Sci* 50(3):1336-43.
- 26  
27 Lotery AJ, Jacobson SG, Fishman GA, Weleber RG, Fulton AB, Namperumalsamy P, Heon E, Levin AV, Grover S, Rosenow JR, Kopp KK, Sheffield VC, Stone EM. 2001. Mutations in the CRB1 gene cause Leber congenital amaurosis. *Arch Ophthalmol* 119(3):415-20.
- 28  
29 Lotery AJ, Namperumalsamy P, Jacobson SG, Weleber RG, Fishman GA, Musarella MA, Hoyt CS, Heon E, Levin A, Jan J, Lam B, Carr RE, Franklin A, Radha S, Andorf JL, Sheffield VC, Stone EM. 2000. Mutation analysis of 3 genes in patients with Leber congenital amaurosis. *Arch Ophthalmol* 118(4):538-43.
- 30  
31 Louie CM, Caridi G, Lopes VS, Brancati F, Kispert A, Lancaster MA, Schlossman AM, Otto EA, Leitges M, Grone HJ, Lopez I, Gudiseva HV, O'Toole JF, Vallespin E, Ayyagari R, Ayuso C, Cremers FP, den Hollander AI, Koenekoop RK, Dallapiccola B, Ghiggeri GM, Hildebrandt F, Valente EM, Williams DS, Gleeson JG. 2010. AHI1 is required for photoreceptor outer segment development and is a modifier for retinal degeneration in nephronophthisis. *Nat Genet* 42(2):175-80.
- 32  
33  
34 Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bencicelli JL, Ying GS, Rossi S, Fulton A, Marshall KA, Banfi S, Chung DC, Morgan JI, Hauck B, Zeleniaia O, Zhu X, Raffini L, Coppieters F, De Baere E, Shindler KS, Volpe NJ, Surace EM, Acerra C, Lyubarsky A, Redmond TM, Stone E, Sun J, McDonnell JW, Leroy BP, Simonelli F, Gauderman JB. 2009. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. *Lancet* 374(9701):1597-605.
- 35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Deleted: .

Deleted: .

- 1  
2  
3 Perrault I, Rozet JM, Calvas P, Gerber S, Camuzat A, Dollfus H, Chatelin S, Souied E, Ghazi I, Leowski C, Bonnemaïson M,  
4 Le Paslier D, Frezal J, Dufier JL, Pittler S, Munnich A, Kaplan J. 1996. Retinal-specific guanylate cyclase gene  
5 mutations in Leber's congenital amaurosis. *Nat Genet* 14(4):461-4.
- 6 Rivolta C, Peck NE, Fulton AB, Fishman GA, Berson EL, Dryja TP. 2001. Novel frameshift mutations in CRX associated with  
7 Leber congenital amaurosis. *Hum Mutat* 18(6):550-1.
- 8 Sayer JA, Otto EA, O'Toole JF, Nurnberg G, Kennedy MA, Becker C, Hennies HC, Helou J, Attanasio M, Fausett BV, Utsch  
9 B, Khanna H, Liu Y, Drummond I, Kawakami I, Kusakabe T, Tsuda M, Ma L, Lee H, Larson RG, Allen SJ,  
10 Wilkinson CJ, Nigg EA, Shou C, Lillo C, Williams DS, Hoppe B, Kemper MJ, Neuhaus T, Parisi MA, Glass IA,  
11 Petry M, Kispert A, Gloy J, Ganner A, Walz G, Zhu X, Goldman D, Nurnberg P, Swaroop A, Leroux MR,  
12 Hildebrandt F. 2006. The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates  
13 transcription factor ATF4. *Nat Genet* 38(6):674-81.
- 14 Seong MW, Kim SY, Yu YS, Hwang JM, Kim JY, Park SS. 2008. Molecular characterization of Leber congenital amaurosis in  
15 Koreans. *Mol Vis* 14:1429-36.
- 16 Shu X, Black GC, Rice JM, Hart-Holden N, Jones A, O'Grady A, Ramsden S, Wright AF. 2007. RPGR mutation analysis and  
17 disease: an update. *Hum Mutat* 28(4):322-8.
- 18 Simonelli F, Ziviello C, Testa F, Rossi S, Fazzi E, Bianchi PE, Fossarello M, Signorini S, Bertone C, Galantuomo S, Brancati  
19 F, Valente EM, Ciccodicola A, Rinaldi E, Auricchio A, Banfi S. 2007. Clinical and molecular genetics of Leber's  
20 congenital amaurosis: a multicenter study of Italian patients. *Invest Ophthalmol Vis Sci* 48(9):4284-90.
- 21 Simovich MJ, Miller B, Ezzeldin H, Kirkland BT, McLeod G, Fulmer C, Nathans J, Jacobson SG, Pittler SJ. 2001. Four novel  
22 mutations in the RPE65 gene in patients with Leber congenital amaurosis. *Hum Mutat* 18(2):164.
- 23 Sohocki MM, Bowne SJ, Sullivan LS, Blackshaw S, Cepko CL, Payne AM, Bhattacharya SS, Khaliq S, Qasim Mehdi S, Birch  
24 DG, Harrison WR, Elder FF, Heckenlively JR, Daiger SP. 2000a. Mutations in a new photoreceptor-pineal gene on  
25 17p cause Leber congenital amaurosis. *Nat Genet* 24(1):79-83.
- 26 Sohocki MM, Perrault I, Leroy BP, Payne AM, Dharmaraj S, Bhattacharya SS, Kaplan J, Maumenee IH, Koenekoop R, Meire  
27 FM, Birch DG, Heckenlively JR, Daiger SP. 2000b. Prevalence of AIPL1 mutations in inherited retinal degenerative  
28 disease. *Mol Genet Metab* 70(2):142-50.
- 29 Stone EM. 2007. Leber congenital amaurosis - a model for efficient genetic testing of heterogeneous disorders: LXIV Edward  
30 Jackson Memorial Lecture. *Am J Ophthalmol* 144(6):791-811.
- 31 Sundaresan P, Vijayalakshmi P, Thompson S, Ko AC, Fingert JH, Stone EM. 2009. Mutations that are a common cause of  
32 Leber congenital amaurosis in northern America are rare in Southern India. *Mol Vis* 15:1781-7.
- 33 Swain PK, Chen S, Wang QL, Affatigato LM, Coats CL, Brady KD, Fishman GA, Jacobson SG, Swaroop A, Stone E, Sieving  
34 PA, Zack DJ. 1997. Mutations in the cone-rod homeobox gene are associated with the cone-rod dystrophy  
35 photoreceptor degeneration. *Neuron* 19(6):1329-36.
- 36 Thompson DA, Li Y, McHenry CL, Carlson TJ, Ding X, Sieving PA, Apfelstedt-Sylla E, Gal A. 2001. Mutations in the gene  
37 encoding lecithin retinol acyltransferase are associated with early-onset severe retinal dystrophy. *Nat Genet*  
38 28(2):123-4.
- 39 Tory K, Lacoste T, Burglen L, Moriniere V, Boddart N, Macher MA, Llanas B, Nivet H, Bensman A, Niaudet P, Antignac C,  
40 Salomon R, Saunier S. 2007. High NPHP1 and NPHP6 mutation rate in patients with Joubert syndrome and  
41 nephronophthisis: potential epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations. *J Am  
42 Soc Nephrol* 18(5):1566-75.
- 43 Travaglini L, Brancati F, Attie-Bitach T, Audollent S, Bertini E, Kaplan J, Perrault I, Iannicelli M, Mancuso B, Rigoli L, Rozet  
44 JM, Swistun D, Tolentino J, Dallapiccola B, Gleeson JG, Valente EM, Zankl A, Leventer R, Grattan-Smith P,  
45 Janecke A, D'Hooghe M, Sznajder Y, Van Coster R, Demerleir L, Dias K, Moco C, Moreira A, Kim CA, Maegawa G,  
46 Petkovic D, Abdel-Salam GM, Abdel-Aleem A, Zaki MS, Marti I, Quijano-Roy S, Sigaudy S, de Lonlay P, Romano  
47 S, Touraine R, Koenig M, Lagier-Tourenne C, Messer J, Collignon P, Wolf N, Philippi H, Kitsiou Tzeli S,  
48 Halldorsson S, Johannsdottir J, Ludvigsson P, Phadke SR, Udani V, Stuart B, Magee A, Lev D, Michelson M, Ben-  
49 Zeev B, Fischetto R, Benedicenti F, Stanzial F, Borgatti R, Accorsi P, Battaglia S, Fazzi E, Giordano L, Pinelli L,  
50 Boccone L, Bigoni S, Ferlini A, Donati MA, Caridi G, Divizia MT, Faravelli F, Ghiggeri G, Pessagno A, Briguglio  
51 M, Briuglia S, Salpietro CD, Tortorella G, Adami A, Castorina P, Lalatta F, Marra G, Riva D, Scelsa B, Spaccini L,  
52 Uziel G, Del Giudice E, Laverda AM, Ludwig K, Permuni A, Suppiej A, Signorini S, Uggetti C, Battini R, Di  
53 Giacomo M, Cilio MR, Di Sabato ML, Leuzzi V, Parisi P, Pollazzon M, Silengo M, De Vescovi R, Greco D,  
54 Romano C, Cazzagon M, Simonati A, Al-Tawari AA, Bastaki L, Megarbane A, Sabolic Avramovska V, de Jong  
55 MM, Stromme P, Koul R, Rajab A, Azam M, Barbot C, Martorell Sampol L, Rodriguez B, Pascual-Castroviejo I,  
56 Teber S, Anlar B, Comu S, Karaca E, Kayserili H, Yuksel A, Akcakus M, Al Gazali L, Sztriha L, Nicholl D, Woods  
57 CG, Bennett C, Hurst J, Sheridan E, Barnicoat A, Hennekam R, Lees M, Blair E, Bernes S, Sanchez H, Clark AE,  
58 DeMarco E, Donahue C, Sherr E, Hahn J, Sanger TD, Gallager TE, Dobyns WB, Daugherty C, Krishnamoorthy KS,  
59 Sarco D, Walsh CA, McKanna T, Milisa J, Chung WK, De Vivo DC, Raynes H, Schubert R, Seward A, Brooks DG,  
60 Goldstein A, Caldwell J, Finsecke E, Maria BL, Holden K, Cruse RP, Swoboda KJ, Viskochil D. 2009. Expanding  
CEP290 mutational spectrum in ciliopathies. *Am J Med Genet A* 149A(10):2173-80.
- Tsang WY, Bossard C, Khanna H, Peranen J, Swaroop A, Malhotra V, Dynlacht BD. 2008. CP110 suppresses primary cilia  
formation through its interaction with CEP290, a protein deficient in human ciliary disease. *Dev Cell* 15(2):187-97.

20 Coppieters et al.

- 1  
2 Valente EM, Brancati F, Silhavy JL, Castori M, Marsh SE, Barrano G, Bertini E, Boltshauser E, Zaki MS, Abdel-Aleem A,  
3 Abdel-Salam GM, Bellacchio E, Battini R, Cruse RP, Dobyns WB, Krishnamoorthy KS, Lagier-Tourenne C, Magee  
4 A, Pascual-Castroviejo I, Salpietro CD, Sarco D, Dallapiccola B, Gleeson JG. 2006a. AHI1 gene mutations cause  
5 specific forms of Joubert syndrome-related disorders. *Ann Neurol* 59(3):527-34.
- 6 Valente EM, Silhavy JL, Brancati F, Barrano G, Krishnaswami SR, Castori M, Lancaster MA, Boltshauser E, Boccone L, Al-  
7 Gazali L, Fazzi E, Signorini S, Louie CM, Bellacchio E, Bertini E, Dallapiccola B, Gleeson JG. 2006b. Mutations in  
8 CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. *Nat Genet* 38(6):623-5.
- 9 Vallespin E, Cantalapiedra D, Riveiro-Alvarez R, Wilke R, Aguirre-Lamban J, Avila-Fernandez A, Lopez-Martinez MA,  
10 Gimenez A, Trujillo-Tiebas MJ, Ramos C, Ayuso C. 2007a. Mutation screening of 299 Spanish families with retinal  
11 dystrophies by Leber congenital amaurosis genotyping microarray. *Invest Ophthalmol Vis Sci* 48(12):5653-61.
- 12 Vallespin E, Lopez-Martinez MA, Cantalapiedra D, Riveiro-Alvarez R, Aguirre-Lamban J, Avila-Fernandez A, Villaverde C,  
13 Trujillo-Tiebas MJ, Ayuso C. 2007b. Frequency of CEP290 c.2991\_1655A>G mutation in 175 Spanish families  
14 affected with Leber congenital amaurosis and early-onset retinitis pigmentosa. *Mol Vis* 13:2160-2.
- 15 Walia S, Fishman GA, Jacobson SG, Aleman TS, Koenekoop RK, Traboulsi EI, Weleber RG, Pennesi ME, Heon E, Drack A,  
16 Lam BL, Allikmets R, Stone EM. 2010. Visual Acuity in Patients with Leber's Congenital Amaurosis and Early  
17 Childhood-Onset Retinitis Pigmentosa. *Ophthalmology* 117(6):1190-8.
- 18 Wang H, den Hollander AI, Moayed Y, Abulimiti A, Li Y, Collin RW, Hoyng CB, Lopez I, Bray M, Lewis RA, Lupski JR,  
19 Mardon G, Koenekoop RK, Chen R. 2009. Mutations in SPATA7 cause Leber congenital amaurosis and juvenile  
20 retinitis pigmentosa. *Am J Hum Genet* 84(3):380-7.
- 21 Yzer S, Leroy BP, De Baere E, de Ravel TJ, Zonneveld MN, Voeselek K, Kellner U, Ciriano JP, de Faber JT, Rohrschneider  
22 K, Roepman R, den Hollander AI, Cruysberg JR, Meire F, Casteels I, van Moll-Ramirez NG, Allikmets R, van den  
23 Born LI, Cremers FP. 2006. Microarray-based mutation detection and phenotypic characterization of patients with  
24 Leber congenital amaurosis. *Invest Ophthalmol Vis Sci* 47(3):1167-76.
- 25 Zernant J, Kulm M, Dharmaraj S, den Hollander AI, Perrault I, Preising MN, Lorenz B, Kaplan J, Cremers FP, Maumenee I,  
26 Koenekoop RK, Allikmets R. 2005. Genotyping microarray (disease chip) for Leber congenital amaurosis: detection  
27 of modifier alleles. *Invest Ophthalmol Vis Sci* 46(9):3052-9.
- 28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Deleted: .

## SUPPLEMENTARY MATERIAL

Supplementary Table S1

Gene	Exon	Forward primer (5'-3')	Reverse primer (5'-3')
<i>CEP290</i>	Exon 2	ttgtggcccaattgtctg	ccacctaagtaaacagaaaagcaac
	Exon 3	ccaagtgcttaattgtgca	ttcccctacacacctttt
	Exon 4	tttactgaacgtctccatgtgc	tggcagatccataaaataggag
	Exon 5	ttctagactcctatftttagatctgc	ttcacaacctatgctcagtc
	Exon 6	atctgcaactgaagtataatgc	tggatgatgacaaaatgaaca
	Exon 7	gggtgggagaattgcttgaac	accccatagacctgagatg
	Exon 8	ttggttctactgagccaataatg	tctgaaggaaccaaacacaaca
	Exon 9	ggtaggctttaagtgtgtg	ctaatgaccaagacaggcaaa
	Exon 10	tgtcaatgcccaattagtaaagg	gtgaggtgattggagaacaca
	Exon 11	ttcaggatgacttcaatgataaa	aactcattgatgaaagaggta
	Exon 12	cagagattatgccagtagttgctc	tgggaccaggtggtagaag
	Exon 13	aaaagcatactgtaccaca	tccatcattacaagttaagcac
	Exon 14	aatggcataccactttcttgc	tggcaaaaagtaaatgctcaag
	Exon 15	gcatagtacatttctttagac	actccaacccataaaaatct
	Exon 16	tcacagaaagttacctcattctc	cctcttcttgagccatttg
	Exon 17	tgtaggccttgaaccaaagac	ttcaggactgaaccactgac
	Exon 18	ggatcacgaggtcagaagat	aaatgagaagcttattggct
	Exon 19	gggattaagatcaccatctgc	acagcaaggcaaatcaactg
	Exon 20	aactcaactattcacgttgattt	ttgaaagcagctcaagaaaaac
	Exon 21	tatcatgcttgcaatgaa	tcttataaggcacttatttccac
	Exon 22	ggcatttctaagcagaaactgaa	atctgcatgcttggatg
	Exon 23	tgtgttcttacagatttggga	caggataatcccaggctaatg
	Exon 24	tgataacttgttgccttgc	tccgaatccatctgaagagc

Gene	Exon	Forward primer (5'-3')	Reverse primer (5'-3')
	Exon 25	gatcaagtccaacaagatgc	cagaagaagcaattatgacaaa
	Exon 26	tgcatgtttttcttacatgg	aatgcaggcaactttaat
	Intron 26	cattagaaagtcctaggcaagagacat c	agtaaggaggatgtaagactggagatagag
	Exon 27	ggacacagccaaacatatac	caggattatcatctgcctaagtt
	Exon 28	tccatggaactataatgcttcc	tctgcttccctttaacaattc
	Exon 29	tttaccctcctcagctctgttc	ttaacctgttaaacaccgatct
	Exon 30	gcaaacatgataacctctgatgg	ctgggcaacagaatgagacc
	Exon 31_1	agtccagctatgtttgcac	ctcgtttggagggaagaaac
	Exon 31_2	ccaagggtaaagctccacta	ttgtagatctcatgtgccact
	Exon 32	caggagaatggcatgaacc	atcattatcatcaatggaggaatgt
	Exon 33	tcacctctcagttgtatt	cagttgcagcattgagagtaa
	Exon 34	atctgtttgtactctgtagcat	tgctattagaacattataggag
	Exon 35_1	aagcatgcaataactgctgtc	accttgctgcatgtttgc
	Exon 35_2	aatcaatgaactgagccttcg	ggtgtaatccaatcacatgcaa
	Exon 36	gaggggacatgcataccagt	cggtagctacaggaggaag
	Exon 37	ttgatcattgaggaacccaaa	ccagcagtcctgaggataaaa
	Exon 38	gttcagtcagccgagattg	acttttattacaacacggagat
	Exon 39	ttcaatgtgaaagaattgagtg	tgctagccaccaacagtcg
	Exon 40_1	tcctcaaggtagactgacatgaa	ttgcctttcagttcatcatic
	Exon 40_2	ctactacctctatattgtaaatcagaca	ttgtgggtgtttggaaga
	Exon 41	aaaatgcagaagcagctacca	ttcaatactgcttatagtcctcaa
	Exon 42	tcaacctgtatagcaaaatgaaca	cgagatcacaggaatcca
	Exon 43	tggatttcctgtgatctcg	tcaattcacatggaaaagaaa
	Exon 44	catttaaaggagccttcagtg	tgagaaagatgtaatgctttgg

Gene	Exon	Forward primer (5'-3')	Reverse primer (5'-3')
	Exon 45	ggctttcaccagaacctcc	ggccttcaacaataaatgct
	Exon 46	tgcatcaggcaataatgtgg	cagatgcagaataaacactgaaa
	Exon 47_1	gctgcatgatttaggaatgtc	caattttctatttctctgctca
	Exon 47_2	tggtagaagtggaaagacaatcc	cccttagccttgcctctcat
	Exon 48	aacgttgggaactcgttct	tggggaatgtgatgacagc
	Exon 49	aggaagaaccagggtatcca	ttgaatacactgaatctatgagaaca
	Exon 50	ttgccaccacttttaatgc	ggggtgcccttcagttagat
	Exon 51	tgctgtctctagttagca	ctaggacaatgccagttatgc
	Exon 52	cgtgaaggcttttattcca	aagacccaaagcttatcaggaa
	Exon 53	ggagggaggcagcattaagt	tgttaggaatagtcagatgaaca
	Exon 54	tgccttattgctgtatttgacc	tcggagaactgcttattcca
<i>CRBI</i>	Exon 1	atgaatccaatccagcctga	tgactgttcacattgactgg
	Exon 2_1	gttgaggcagcacaagggtc	gctcctttctcctggggtg
	Exon 2_2	caatccctgtcaaggaagtg	ggagtaacctcaaltccatc
	Exon 2_3	gagtgcttccagcccttg	gagctaactacacatctgtg
	Exon 3	ctctgtaaacaagcattgtc	cagggagtcttaagccaatc
	Exon 4	agtaagatgatccatgggt	tcatttgcataagcgatagtgt
	Exon 5	gacttagcagttctctgaatt	gtcaagtcatatcccactcc
	Exon 6_1	cctgagctattcatgcacttc	gaagtgagggatgcatgttcc
	Exon 6_2	gatatttctcctgggtgtacc	gaagagccattggctgaacag
	Exon 6_3	ggctcagttgtaacatagcc	ggagtcgtcgattaaggttaag
	Exon 6_4	ccagcgatggagagtggca	ctacaacgaaggtgtggatg
	Exon 6_5	ggtgttgcctctgcttaacttc	ctgctctgctctgaggcatg
	Exon 7_1	gtcttccatcccttctgtct	tttgggagagtttggagtca
	Exon 7_2	agatttggccaggatgactc	aggccaccaatgtagatgac

24 Coppieters et al.

Gene	Exon	Forward primer (5'-3')	Reverse primer (5'-3')
	Exon 7_3	gactgaacttaatggtggattc	ggtgggtcagtaacatcacc
	Exon 8	cagatatgtggtttcaccgtc	gtcgcaacttaactggtgag
	Exon 9_1	caatgatcattactattaataacgg	gtgccatcattcactgactgc
	Exon 9_2	tcaattgcaaagtggcaaca	ttaactgcaaacagccagtg
	Exon 9_3	caataataaggcctgcaagg	ctgcaactctgtcagagcag
	Exon 9_4	cactgtgaactcaacatcgatg	cagtgtgacagagtatagcttc
	Exon 10	gaacaagatgaacagctgtgg	gctcagaattctctccagaag
	Exon 11	ccaatgtattcaacagggacc	caactggctcgtcattcatac
	Exon 12	ctttgctatagaattcgcac	gtacagtcacacattcacag
	Exon 1	ctcaagactgcttccaaacc	tcccaaagccataactcctt
	Exon 2	ctatctctcggactttgag	ggaagccagagaagagagac
	Exon 3	ccaagggcaggataagaag	ctaggccctactttgaggag
	Exon 4	ttgtcagtaaccttactcctc	atggccattctaagctcca
	Exon 5	ggcttgaaaactactggactg	ctgaacatcacctagcactg
	Exon 6	cctagggacaaaagtataatg	cacaatacagtaactttctcac
<i>RPE65</i>	Exon 7	gtatcaaagtaggcaaagca	cgtttccaaatctgctgcta
	Exon 8	gtggcttgagaatcagccct	catcttctcagaatcacaac
	Exon 9	caagtttgattctgaagaag	ccgtaattccaggaacaatg
	Exon 10	cattgcctgtctcatgtttg	cctgagagagatgaaacattc
	Exon 11	gaattcttctgctcactgag	gagcacatgcttaggaaaactc
	Exon 12	caaagatgggttctgatggg	cctcgtcaaggtgagatga
	Exon 13	acgaactaacatacagaactgc	tcactttgtccagatagggt
	Exon 14	gacattcaatctatagcttggg	gcagacctgaagctgatttc
<i>GUCY2D</i>	Exon 2_1	catgggttactcgggcttg	gagaagatggggctcgaag
	Exon 2_2	atcatccatgggttactcg	gcgatcccggcttctt

Gene	Exon	Forward primer (5'-3')	Reverse primer (5'-3')
	Exon 2_3	tcgtgggtccggtgaa	gtagtggatcgttcgaagg
	Exon 3	ggacggcggcgagccaag	tcccctcccctgcctct
	Exon 4	gtgggctgtgaccccgacc	tggtccatggcgattgtctc
	Exon 5	ctatcattcccagcctctcc	ttgctgcagacttccatttc
	Exon 6	gacggaacttgggcccttgg	ggaaggaaccaaatlacgga
	Exon 7	ctcagcctgacctcaacca	tctcctgagagtgcgcctc
	Exon 8	gcattctggacagtgagcc	agaaaccgatggccacctag
	Exon 9	ccccacattgccctgggcaga	cctgccccaggacgtcacc
	Exon 10	agcaggctgaggctcctct	cccggtgatcctcgtctgc
	Exon 11	ctttctctgagatggctct	ttagaggaaagagtgggct
	Exon 12	caggccagggtcagaggcagc	ctcaggttgcctgacaagcat
	Exon 13	cagcttaccagctctcttc	gcaggcagtgaggtcacctg
	Exon 14	gaccggctgcttacaca	gctggaggctgggtgaag
	Exon 15	ggcaatcgttcgtgtactc	gatggctggagcctgggaa
	Exon 16	ccccgagccctacctaggt	acctccccgtcttgcctccg
	Exon 17	gcattcaccaggtccat	aggggtgagctgaggtttg
	Exon 18	caaacctcagctaccctt	tctaagtcagaaaggatcgg
	Exon 19	gatgacgtggccctgcctccc	cttgggtgggacgttctgcag
<i>AIP1</i>	Exon 1	gcacacctggaatgttgaa	aaaggtggatgggataggag
	Exon 2	gggcttgaacagtgtct	ttcccgaacacagcagc
	Exon 3	agtgaggagcaggattc	tgccatgatccccgtctc
	Exon 4	ctctgcccagggaga	gggagatgtccacagg
	Exon 5	aaagtcaggaaggctatgg	taaggaacctgcagaccaag
	Exon 6	ctggaaggagctgtag	aaaagtacaccacgatcc
<i>CRX</i>	Exon 2	gtgcacgtcaccctatggtgagtaac	cagaggtcctcaagatgaggcc

Gene	Exon	Forward primer (5'-3')	Reverse primer (5'-3')
<i>RDH12</i>	Exon 3	gtagaaggcagggaaatgt	ctcctccatcactctttgt
	Exon 4_1	gctggatgcaaagtagacag	ccatgggagaaaggtagg
	Exon 4_2	tctccgagctcctatttcag	gatctaaactgcagggaagc
	Exon 3	ggagaggagcagagaagcag	gcttccagtgcaggtctttg
	Exon 4	tcttagtgtagctcgtgaagg	ttctagtgcagagccccaag
	Exon 5	cccagtcceaagctcactta	tagtggggtgatgatggtt
	Exon 6	gggcaattatgcaggtctgt	ccctggacattctccacatt
	Exon 7	aattggttcacaccagaaga	tgactccaagttgctgtg
	Exon 8	tctgagtcctccttctca	tcatcaggcacaactcagc
<i>RPGRIPI</i>	Exon 9	gggaccataaagatttcaga	ctttagggtggccttctcc
	Exon 1	tgctgagaaattcctgctacaa	tctgtgaaggccagcaagat
	Exon 2	tgagacatctaaagggtcaaaaa	cagtctatc gacatgtttggc
	Exon 3	tgactgggacagaaggcta	aaacgtggctggcacatc
	Exon 4	cagccctcatgttccagtt	ttccctgatcatgctgaaaa
	Exon 5	ccaaggtactgattcacttaattc	cctctgagatggaggaaaagg
	Exon 6	cgtagatgagaaatgggagaaa	cgagttgtgaggcttgatt
	Exon 7	agtggtctaagtaacagtacct	atttctccagcaataggc
	Exon 8	caaagtcattcttttgacatctg	ggagcttcgtttttgcattt
	Exon 9	ggaaaatcctcattaatccaat	attgagtaccaattcccata
	Exon 10	aggccaggagatgctgaaa	ggatcaagtgagggattaaa
	Exon 11	tttttttcggagtcaag	gttttctaattcatcatcttccc
	Exon 12	agtttctgctgctggcattt	ggacagccattgtgtttg
	Exon 13	gggtctgaaggaaatcaaa	atgagaggcaccttctga
	Exon 14	cacaactggactccacca	ggggaatacagatggtgtgg
Exon 15	agcaccaatgcagaatttcc	gatgtagctcgtccaaagg	

Gene	Exon	Forward primer (5'-3')	Reverse primer (5'-3')
	Exon 16	gctcttctcaccacagatcc	tctgctctgttctcttgaca
	Exon 17	ggctgctgacaaatgctcact	cacatgacactcacagaggga
	Exon 18	tcccaaatccctttcttg	tgtctgcttctgctctgct
	Exon 19	aaagaaggcaggaagggaagg	cttgaagcctgatctcgtg
	Exon 20	tgaccagacagtggattgga	tgcattttccatcagcttca
	Exon 21	tgggtaattggatggcgta	atcaccaccacaaaatcca
	Exon 22	ccatgaataccactaatgaaagtct	catcagcacaaaaccaaac
	Exon 23	aaatggaggcaaggaaaag	gggataagattcaatccacttg
	Exon 24	cattcatttagcatccccagt	ggtactggagaaaaatgccttag
<i>AHI1</i>	Exon 1_1	agggcactgtcatgatctcc	ggtaaacatgtcccgtgtg
	Exon 1_2	tcagtccatcagaacagact	ggctggactggcaacaatg
	Exon 1_3	cacagcgggacatgtttacc	ggcaggagaattgcttgacc
	Exon 1_4	ggaacattgtgccagtcca	cgtggcctttgagttcagtt
	Exon 1_5	tctgggcatagcatcacaca	atgctaacaatgtttgagaggca
	Exon 2	ttgtccttctgaccatgc	ggccctagatcaaaagcctca
	Exon 3	tggtgacacagcaagactc	tggtcacatacctgaaagctga
	Exon 4	actttggctccttgcctcat	agcaggctcctggtaaatgt
	Exon 5	aactgtgcatgagcaggt	agcaaaccttgagacagcct
	Exon 6	agagaaatgaagcataatggcct	acacatcttgcgctattgct
	Exon 7	ttgcccittaatgggatgtga	tgacctatcatgtgtctggt
	Exon 8	tggtgcattccagttcttgg	tgccatttgttgggcaagt
	Exon 9	aggtgtggtcatctgttca	cccatcccagtttacatggc
	Exon 10	aattgcggacacgaaagaca	gaggagggtcagtggaatgt
	Exon 11	tgtgttagcctcattaaacgc	aaactccctgggctcttgg
	Exon 12	actgccagatgtccttgg	cagccctaaactgacgttactc

28 Coppieters et al.

Gene	Exon	Forward primer (5'-3')	Reverse primer (5'-3')
	Exon 13	atgccacagtcaaatggg	acacatgtactgagaggctcat
	Exon 14	gccccgccacatattattc	ggttcattggctgtgttggt
	Exon 15	gcaccactggattctacct	tgtgctgcaaatgtcttgggt
	Exon 16	gctatcaactagccacattggac	tggcagtgatggcttagagt
	Exon 17	ggcctccagaactgtgagaa	ggtgaagaagcagaacaaaagga
	Exon 18	tcaactcctgctttaaatcaacctt	gttcagcgtgaaatctggca
	Exon 19	ggcatggctgtttgtgtctt	atggaccctcctaactgaatg
	Exon 20	cgtctcacttgattccacagc	tcattgtaccaggctggct
	Exon 21	tgaggcagtagaatcgcttga	ggtttgctgttctctggctt
	Exon 22	gagatcgtgccactgcattc	cattfactggcagcagggt
	Exon 23	ggcagatgcccttaaatgctc	tcttcactcttttgcaat
	Exon 24	agcacaatgaaggaaagcca	tcattcttagcaccgaatgtt
	Exon 25	cctgtaggacagcactcaaga	acaggctaggecacaccttag
	Exon 26	cctgtccatctgagtcecaa	tcactgtgagtgtgtaccc
	Exon 27	ggaatgctaaacgcagcaca	gctgatagcgtagtaccga
	Exon 28	cgctggctactacgctatca	tttcctgcgctagctacaa

Supplementary Table S1: Exon-flanking primers for the amplification of the human *CEP290*, *CRB1*, *RPE65*, *GUCY2D*, *AIPL1*, *CRX*, *RDH12*, *RPGRIP1* and *AH11* genes and for the c.2991+1655A>G mutation in *CEP290*.

## MUTATION IN BRIEF

## HUMAN MUTATION

Supplementary Table S2

Gene	Nucleotide change	Amino acid change	Domain/Region	PolyPhen		SIFT			Grantham score	Nucleotide conservation	Amino acid conservation	Remarks
				Prediction	PSIC score difference	Prediction	Score	Median sequence conservation				
<i>CEP290</i>	c.5081T>C	p.Leu1694Pro UV	Coiled coil	Possibly damaging	1.995	Affect protein function	0.00*	3.44	98	Weakly conserved (score: 0.0)	Moderately conserved (considering 12 species)	
<i>CEP290</i>	c.4696G>C	p.Ala1566Pro UV	Coiled coil	Possibly damaging	1.638	Tolerated	0.10	3.44	27	Highly conserved (score: 1.0)	Highly conserved, up to Frog (considering 12 species)	
<i>CRB1</i>	c.929G>A	p.Cys310Tyr	EGF-like 8, extracellular domain	Probably damaging	3.761	Affect protein function	0.00*	3.96	194	Highly conserved (score: 1.0)	Highly conserved, up to Cow (considering 8 species)	Disruption of annotated bond formation site (PolyPhen)
<i>CRB1</i>	c.1472A>T	p.Asp491Val UV	Laminin G-like 1, extracellular domain	Benign	1.410	Affect protein function	0.01*	3.96	152	Highly conserved (score: 1.0)	Weakly conserved (considering 8 species)	
<i>RPE65</i>	c.253C>T	p.Arg85Cys		Probably damaging	2.476	Tolerated	0.05	2.90	180	Highly conserved (score: 1.0)	Moderately conserved (considering 18 species)	
<i>RPE65</i>	c.542C>T	p.Pro181Leu		Probably damaging	2.956	Affect protein function	0.04	2.90	98	Highly conserved (score: 1.0)	Highly conserved, up to Fruitfly (considering 18 species)	Located next to metal ion binding site (UniProtKB)
<i>GUCY2D</i>	c.587A>T	p.Glu196Val UV	Extracellular domain	Possibly damaging	1.650	Affect protein function	0.00*	4.32	121	Weakly conserved (score: 0.3)	Highly conserved, up to Opossum (considering 10 species)	
<i>GUCY2D</i>	c.1724C>T	p.Pro575Leu	Cytoplasmic	Benign	1.433	Affect	0.00*	4.32	98	Weakly	Highly	rs28743021

Received &lt;date&gt;; accepted revised manuscript &lt;date&gt;.

© 2010 WILEY-LISS, INC.

Gene	Nucleotide change	Amino acid change	Domain/Region	PolyPhen		SIFT			Grantham score	Nucleotide conservation	Amino acid conservation	Remarks
				Prediction	PSIC score difference	Prediction	Score	Median sequence conservation				
		UV	domain			protein function				conserved (score: 0.0)	conserved, up to Opossum (considering 10 species)	
<i>GUCY2D</i>	c.2132C>T	p.Pro711Leu UV	Protein kinase, Cytoplasmic domain	Probably damaging	3.140	Affect protein function	0.00*	4.32	98	Highly conserved (score: 1.0)	Highly conserved, up to Opossum (considering 10 species)	
<i>GUCY2D</i>	c.2598G>C	p.Lys866Asn	Cytoplasmic domain	Probably damaging	2.236	Affect protein function	0.00*	4.32	94	Highly conserved (score: 1.0)	Highly conserved, up to Opossum (considering 10 species)	
<i>AIPL1</i>	c.341C>T	p.Thr114Ile UV	PPIase FKBP-type	Benign	0.179	Tolerated	0.13	3.34	89	Weakly conserved (score: 0.0)	Moderately conserved (considering 12 species)	rs8069375
<i>AIPL1</i>	c.1126C>T	p.Pro376Ser UV		Benign	?	Tolerated	0.48	4.32	74	Weakly conserved (score: 0.0)	Weakly conserved (considering 12 species)	
<i>CRX</i>	c.425A>G	p.Tyr142Cys UV		Benign	1.458	Affect protein function	0.00*	4.32	194	Highly conserved (score: 1.0)	Highly conserved, up to Little brown bat (considering 8 species)	<a href="#">rs61748442</a>
<i>CRX</i>	c.724G>A	p.Val242Met UV		Benign	1.033	Tolerated	0.20	4.32	21	Weakly conserved (score: 0.2)	Highly conserved, up to Dog (considering 8 species)	RS61748459 VAR_007949
<i>RDH12</i>	c.524C>T	p.Ser175Leu		Probably damaging	Prediction basis: sequence annotation	Affect protein function	0.00*	3.61	145	Weakly conserved (score: 0.2)	Highly conserved, up to Fruitfly (considering	Disruption of annotated binding site (PolyPhen)

Gene	Nucleotide change	Amino acid change	Domain/Region	PolyPhen		SIFT			Grantham score	Nucleotide conservation	Amino acid conservation	Remarks
				Prediction	PSIC score difference	Prediction	Score	Median sequence conservation				
											15 species)	
<i>RDH12</i>	c.698T>A	p.Val233Asp		Probably damaging	2.616	Affect protein function	0.00*	3.60	152	Weakly conserved (score: 0.0)	Highly conserved, up to Fruitfly (considering 15 species)	
<i>AHII</i>	c.2273A>C	p.His758Pro	WD 4	Probably damaging	2.679	Affect protein function	0.03*	3.39	77	Highly conserved (score: 1.0)	Moderately conserved (considering 12 species)	
<i>AHII</i>	c.2433T>G	p.Asn811Lys	WD 5	Possibly damaging	1.719	Affect protein function	0.00*	3.39	94	Highly conserved (score: 1.0)	Highly conserved, up to <i>Tetraodon</i> (considering 12 species)	
<i>AHII</i>	c.3368C>T	p.Ser1123Phe		Probably damaging	Prediction basis: sequence annotation	Tolerated	0.07	3.67	155	Highly conserved (score: 0.9)	Weakly conserved (considering 12 species)	Disruption of annotated functional site (modified residue) (PolyPhen)

**Supplementary Table S2: *in-silico* predictions of the novel missense variants and known unclassified variants identified in this study using the Alamut software.**

Alamut provides for each variant the HGVS nomenclature and a nucleotide conservation score which was computed at UCSC from 17 vertebrates and has a range between 0 and 1 (<http://genome.ucsc.edu/cgi-bin/hgTrackUi?g=multiz17way>). For missense variants, Alamut calculates the Grantham distance and automatically fills in queries for PolyPhen and SIFT prediction servers, based on the UniProt protein identifiers and FASTA sequences of several orthologs, respectively. In addition, information on topological as well as functional domains and variations (VAR) was extracted from the UniProtKB database using the following identifiers: O15078 (*CEP290*), P82279 (*CRB1*), Q16518 (*RPE65*), Q02846 (*GUCY2D*), Q9NZN9 (*AIPL1*), O43186 (*CRX*), Q96NR8 (*RDH12*) and Q8N157 (*AHII*) (<http://www.uniprot.org/uniprot/>). Variants were designated as “unclassified variant (UV)” if no consensus was seen in all prediction programs used. \*These substitutions may have been predicted to affect function just because the sequences used were not diverse enough.

32 Coppieters et al.

Supplementary Table S3 – Part I

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
<a href="#">CEP290</a> <a href="#">p.[Cys998X]+</a> <a href="#">[Cys998X]</a>	LCA-1	M			Absent (4mo)		Optic disc pallor Retinal vessel attenuation Normal macula	
<a href="#">CEP290</a> <a href="#">p.[Cys998X]+</a> <a href="#">[Cys998X]</a>	LCA-2	M		Mild	Absent (5mo & 1.5yrs)		Pigmentary retinopathy Normal macula (6yrs) Retinal vessel attenuation Salt and pepper alterations Pseudopapilledema HyperAF ring around macula (14yrs)	Eyepoking
<a href="#">CEP290</a> <a href="#">p.[Cys998X]+</a> <a href="#">[Arg108X]</a>	LCA-3	M	+	+	Absent (4mo)	+ (6yrs)	Normal optic discs Retinal vessel attenuation Normal peripheral retina Beginning of hyperAF around macula (6yrs)	Eyepoking Enophthalmos
<a href="#">CEP290</a> <a href="#">p.[Cys998X](+)</a> <a href="#">[Gln899X]</a>	LCA-4	F			Absent (2yrs)		Retinal vessel attenuation Tapetal reflex of posterior pole Pseudopapilledema	
<a href="#">CEP290</a> <a href="#">p.[Cys998X](+)</a> <a href="#">[Arg1465X]</a>	LCA-5	M			Absent (4mo)			Eyepoking Enophthalmos
<a href="#">CEP290</a> <a href="#">p.[Cys998X]+</a> <a href="#">[Lys1575X]</a>	LCA-6	F	-	Strong (since 3.6yrs)	Severe CRD (3.3yrs)	B/R and G/R	Retinal vessel attenuation White marbleized changes Macular oedema (3.2yrs) Retinal vessel attenuation White marbleized around vascular arcade Discrete RPE alterations No macular reflex (4.9yrs) Extensive peripheral outer retinal atrophy Limited spicular intraretinal pigmentation Relative macular preservation Relatively darker perifoveal ring	Exotropia

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
							(18yrs)	
<i>CEP290</i> <a href="#">p.[Cys998X(+) Lys1575X]</a>	LCA-7	M	(+) (later in life)	+ (early in life)	Subnormal (1yr) Absent (21yrs)	+ (early in life)	Peripheral salt and pepper intraretinal pigmentation Relative macular preservation (22yrs) Extensive midperipheral and peripheral outer retinal atrophy Limited spicular intraretinal pigmentation Relative macular preservation Development of synchysis scintillans (33yrs) More extensive intraretinal pigmentation (predominantly spicular) Relative macular preservation Hyper AF in central macula and mid- and far periphery Extensive confluent atrophy (49yrs)	Eyepoking Enophthalmos Exotropia Posterior SCP cataract (star shaped) (49yrs)
<i>CEP290</i> <a href="#">p.[Cys998X(+) Lys1575X]</a>	LCA-8	F			Absent (16yrs)	R/G	Optic disc pallor	
<i>CEP290</i> <a href="#">p.[Cys998X] Arg1782X]</a>	LCA-9	M		+	Severe CRD (5mo & 1.2yrs)		Marbleized retinal changes	
<i>CEP290</i> <a href="#">p.[Cys998X] Asp128Glufs X17]</a>	LCA-10	F					Nummular pigmentation Pseudopapilledema Maculopathy	Deleted: ND
<i>CEP290</i> <a href="#">p.[Cys998X] Glu146Glyfs X17]</a>	LCA-11	M			Absent (6mo)		Optic disc pallor Yellow confluent peripheral spots	Eyepoking Enophthalmos
<i>CEP290</i> <a href="#">p.[Cys998X(+) Arg621IlefsX 2]</a>	LCA-12	M			Absent		Retinal vessel attenuation Peripheral pepper and salt alterations Macular RPE alterations (6mo)	Enophthalmos
<i>CEP290</i> <a href="#">p.[Cys998X(+) Leu1141Phef]</a>	LCA-13	F			Absent (4mo)		Optic disc pallor Retinal vessel attenuation	

34 Coppieters et al.

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
<a href="#">sX5</a>								
<a href="#">CEP290 p.Cys998X1+ Thr1334IlefsX2</a>	LCA-14	F			Absent (5mo)		Granular pigment alterations Normal macula (7mo)	Eyepoking Enophthalmos Cataract
<a href="#">CEP290 p.Cys998X(+Glu1656AsnfsX3</a>	LCA-15 (Perrault, Delphin et al. 2007)	M		-	Absent		Retinal vessel attenuation (7mo) Hyperaemic optic disc Marbleized, white spots Nummular pigmentation (2yrs)	Eyepoking Enophthalmos
<a href="#">CEP290 p.Cys998X1+ Ala1832ProfsX19</a>	LCA-16	M			Absent (6mo & 10mo)		Yellow spots	Eyepoking
<a href="#">CEP290 p.Cys998X1+ Lys1840ArgfsX5</a>	LCA-17	M			Absent (5mo)		Full optic disc with no apparent excavation Marbleized fundus changes in the midperiphery Normal macula (8yrs)	Eyepoking
<a href="#">CEP290 p.Cys998X1+ Glu1956GlvfsX9</a>	LCA-18	M		+ (early in life)	Absent (3mo)		Full optic discs Limited outer retinal atrophy Midperipheral salt and pepper alterations Normal macula (15yrs)	Eyepoking Enophthalmos Keratoconus with acute hydrops (OD>OS) (13yrs)
<a href="#">CEP290 p.Cys998X1+ Donor Splice defect</a>	LCA-19	M	+	+	Absent (3mo)		Very small optic disc excavation Retinal vessel attenuation Mild midperipheral salt and pepper alterations Bull's eye maculopathy with preservation of central macula, surrounded by concentric area of more pronounced outer retinal atrophy (14yrs)	Eyepoking Enophthalmos
<a href="#">CEP290 p.Cys998X(+ Acceptor Splice defect</a>	LCA-20 (Yzer, Leroy et al. 2006)	F	-	-	Absent (9yrs)		Optic disc pallor Retinal vessel attenuation RPE alterations maculopathy unknown (3mo)	Eyepoking Enophthalmos Cataract with lens luxation Keratoconus (OD) Enucleation because

Field Code Changed

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
								of phacolytic glaucoma (OD)
<i>CEP290</i> <a href="#">p.[Cys998X]+[Acceptor splice defect]</a>	LCA-21	M	+		Absent		Optic disc pallor Retinal vessel attenuation	
<i>CEP290</i> <a href="#">p.[Cys998X(+)]Acceptor Splice defect]</a>	LCA-22	M	-	-	Absent (4mo & 9mo)		Normal optic discs White retinal spots Tapetal reflex	
<i>CEP290</i> <a href="#">p.[Cys998X(+)]Acceptor Splice defect]</a>	LCA-23	F			Absent (5mo & 1.5yrs)		Salt and pepper alterations Normal macula (5mo) Pinkish optic disc Mild retinal vessel attenuation RPE alterations (yellowish dots) (6yrs)	Eyepoking Enophthalmos
<i>CEP290</i> <a href="#">p.[Lys1575X(+)]Lys1575X]</a>	LCA-24	M						
<i>CEP290</i> <a href="#">p.[Lys1575X]+[Ala1566Pro]</a> 1	LCA-25	M	-	Strong	Severe CRD (1.1yrs)		No RPE alterations (4mo) Retinal vessel attenuation Discrete RPE alterations (1.10yrs) Retinal vessel attenuation HyperAF ring around macula (8yrs) Retinal vessel attenuation Salt and pepper alterations Mild macular pigment epithelial alterations (10yrs)	Eyepoking Enophthalmos Exotropia
<i>CEP290</i> <a href="#">p.[Leu1694Pro]+[=, splice site]</a>	LCA-26		-		Absent (4.5yrs)		No retinal vessel attenuation No hyperpigmentation Midperipheral reticular aspect, especially around vascular arcades Assymmetric ectopia foveae OS>OD	Strabismus

36 Coppieters et al.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
							(3yrs) Normal optic disc Deep intraretinal white spots along vascular arcades HyperAF ring around macula No pigmentation/atrophy	
<a href="#">CEP290</a> <a href="#">p.Cys998X</a>	LCA-27	M			Subnormal (5mo & 1yr & 7yrs)	+	(5.4yrs) Optic disc pallor No RPE alterations <del>Normal macula</del>	
<a href="#">CEP290</a> <a href="#">p.Trp7Cys</a> <a href="#"> </a> <a href="#">Trp7Cys</a>	SLS-1	F			Absent (2mo)		Abnormal RPE	
<a href="#">CEP290</a> <a href="#">p.Lys1575X</a> <a href="#"> </a> <a href="#">Arg1465X</a>	SLS-2	F	+			+(12yrs)		Keratoconus Cataract
<a href="#">CEP290</a> <a href="#">p.Lys1575X</a> <a href="#"> </a> <a href="#">Arg1465X</a>	SLS-3	M						Eyepoking
<a href="#">CEP290</a> <a href="#">p.Lys1575X</a> <a href="#"> </a> <a href="#">Arg1465X</a>	CORS-1 (Brancati , Barrano et al. 2007)	F						Enophthalmos
<a href="#">CEP290</a> <a href="#">p.Gln1265X</a> <a href="#"> </a> <a href="#">Acceptor</a> <a href="#">splice defect</a>	LCA-JS- 1	M		-	Absent (first year of life)		Optic disc pallor Salt and pepper alterations Mild spicular intraretinal pigmentation	
<a href="#">CEP290</a> <a href="#">p.Thr2457Ala</a> <a href="#"> </a> <a href="#">X27</a> <a href="#"> </a> <a href="#">Thr</a> <a href="#">2457Ala</a> <a href="#">X27</a> <a href="#"> </a>	LCA-JS- 2 II-1	F	+	+	Absent		Normal optic discs Retinal vessel attenuation Salt and pepper alterations	
<a href="#">CEP290</a> <a href="#">p.Leu2448Thr</a> <a href="#"> </a> <a href="#">X8</a> <a href="#"> </a> <a href="#">Acceptor</a> <a href="#">splice</a> <a href="#">defect</a>	LCA-JS- 3	M		+	Absent (4mo & 1.4yrs)		Optic disc pallor Retinal vessel attenuation	

Deleted: [

Deleted: (+)?]

Field Code Changed

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
<a href="#">CRBI p.[Lys801X(+ )Lys801X]</a>	LCA-28	M					Marbleized fundus changes	
<a href="#">CRBI p.[Lys801X(+ )Gln362X]</a>	LCA-29 (Yzer, Leroy et al. 2006)	M	+	Mild	Absent (1yr & 30.6yrs)	Basic Severe R-G and B-Y deficiency	Optic disc pallor Retinal vessel attenuation Perivascular fibrosis No clear PPRPE Fine intraretinal white flecks Nummular intraretinal pigmentation Macular atrophy (30.6yrs)	Eyepoking (mild) Enophthalmos (mild) Posterior subcapsular cataract (OS>OD)
<a href="#">CRBI p.[Lys801X(+ )Arg764Cys]</a>	LCA-30	M						
<a href="#">CRBI p.[Lys801X(+ )Cys896X]</a>	LCA-31 (Yzer, Leroy et al. 2006)	M	+	-	Absent (3mo)	Basic	Retinal vessel attenuation Outer retinal atrophy RPE defects around vascular arcade Perimacular atrophic spots (3mo) Normal optic discs Perivascular fibrosis No clear PPRPE Outer retinal atrophy Small white dots Nummular hyperpigmentation Pseudopapilledema Macular atrophy (8yrs)	Eyepoking Enophthalmos Exotropia
<a href="#">CRBI p.[Lys801X(+ )Cys896X]</a>	LCA-32 (Yzer, Leroy et al. 2006)	F	+	- (+ after keratoconus)			<a href="#">Depigmentation around macula (15yrs)</a> Macular aplasia: vessels of choroid become apparent (17yrs) Normal optic disc Retinal vessel attenuation Perivascular fibrosis No clear PPRPE Outer retinal atrophy	Eyepoking Enophthalmos Esotropia Keratoconus with acute hydrops and rupture of Descemet membrane (20yrs)

**Deleted:** Depigmentation around macula (15yrs)

**Deleted:**

38 Coppieters et al.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
							White retinal spots Peripheral intraretinal pigment migration, predominant nummular Some midperipheral lipofuscin depositions Macular aplasia Pseudopapilledema (33yrs)	
<a href="#">CRBI</a> <a href="#">p.[Lys801X(+)]</a> <a href="#">[Cys948Tyr]</a>	LCA-33	F	+		Absent (9mo & 1.7yrs)		Pale and slightly swollen optic disc Diffuse outer retinal atrophy Small whitish deep intraretinal flecks Nummular intraretinal pigmentation Limited macular atrophy	
<a href="#">CRBI</a> <a href="#">p.[Lys801X]+</a> <a href="#">[Acceptor splice defect]</a>	LCA-34	F		+	Absent (4mo & 1.5yrs)		Retinal vessel attenuation Macular pigmentation Pseudopapilledema	Eyepoking Strabismus
<a href="#">CRBI</a> <a href="#">p.[Cys948Tyr]</a> <a href="#">+[Cys948Tyr]</a>	LCA-35	F						Keratoconus (OS)
<a href="#">CRBI</a> <a href="#">p.[Cys948Tyr]</a> <a href="#">+[Glu1330X]</a>	LCA-36	F					Optic disc pallor Retinal vessel attenuation Nummular intraretinal pigmentation Macular alterations Coats reaction	Enophthalmos Cataract Glaucoma (neovascular with OD seclusio pupillae and anterior synechia)
<a href="#">CRBI</a> <a href="#">p.[Cys948Tyr]</a> <a href="#">+[Splice defect]</a>	LCA-37	M	+					
<a href="#">CRBI</a> <a href="#">p.[Cys948Tyr]</a> <a href="#">+[Splice defect]</a>	LCA-38	M	+	-	Absent (9.1yrs)	Basic (until 9yrs) Disturbed (after 9yrs)	Optic disc pallor with irregular shape Retinal vessel attenuation Peripheral salt and pepper alterations (6yrs) Retinal vessel attenuation with tortuous aspect Extensive peripheral and macular outer retinal atrophy Small white deep intraretinal flecks	Eyepoking Enophthalmos Exotropia

Deleted:

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
							<p>Nummular intraretinal pigment migrations</p> <p>Yellowish hue of the macula</p> <p>6 astrocytoma-like retinal excrescences superior to right macula</p> <p>Pseudopapilledema with prominent sheathing of blood vessels near optic discs (18yrs)</p>	
<a href="#">CRBI p.[Cys948Tyr]+[Splice defect] (LCA-39a) and p.[Splice defect]+[Splice defect] (LCA-39b)</a>	LCA-39a	F	+	+	Absent (4mo)	Basic (early in life) Declining at the age of 12yrs Absent (15.11yrs)	<p>Optic disc pallor</p> <p>Retinal vessel attenuation</p> <p>Salt and pepper aspect</p> <p>Macular aplasia</p> <p>Total chorioretina atrophy in the central macula</p> <p>Pseudopapilledema</p> <p>Atrophic macular region with pigment near border (3yrs)</p> <p>Total atrophy of retina and choriocapillaris</p> <p>Midperipheral small white dots</p> <p>Midperipheral small nummular pigmentation</p>	<p>Eyepoking</p> <p>Enophthalmos</p> <p>Esotropia</p>
	LCA-39b	M		+	Absent (8yrs & 16yrs)	-	<p>Optic disc pallor</p> <p>Small excavation optic disc (OD, not OS)</p> <p>Retinal vessel attenuation</p> <p>Extensive peripheral outer retinal atrophy</p> <p>Limited nummular intraretinal pigmentation</p> <p>Macular yellowish atrophy (OD&gt;OS) (16yrs)</p>	
<a href="#">CRBI p.[Splice defect(+)]Splice defect]</a>	LCA-40	M	+	-	Absent (2yrs)		<p>No optic disc excavation</p> <p>No perivascular sheathing</p> <p>Severe outer retinal and central macular atrophy</p> <p>Small deep intraretinal white flecks</p> <p>Extensive nummular intraretinal pigmentation (11yrs)</p>	<p>Cataract (OS&gt;OD)</p> <p>Retinal detachment (OD: partial - inferior, OS: total)</p>
<a href="#">CRBI p.[Leu814ArgfsX23]+[Cys1240ProfsX24]</a>	LCA-41 II-1	F	+	Mild	Absent (31yrs)	Disturbed	<p>Hyperaemic optic disc</p> <p>Retinal vessel attenuation</p> <p>Small pigment clumps scattered through retina</p> <p>Pseudopapilledema</p> <p>Normal macula (12yrs)</p>	<p>Eyepoking</p> <p>Enophthalmos</p> <p>Esotropia</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
							Macular atrophy with pigment clumping (21yrs) Macular pseudocoloboma (23yrs) Limited perivascular sheathing around optic disc Extensive outer retinal atrophy Small white intraretinal flecks Pronounced nummular intraretinal pigmentation Central macular atrophy (36yrs)	
	LCA-41 II-2	F	+	-	Absent (24yrs)	Disturbed	Beginning macular atrophy with pigment alterations (10yrs) Extensive peripheral outer retinal atrophy Extensive macular atrophy Extreme hyperpigmentation around central macula Pronounced peripapillary perivascular fibrosis Relative sparing of small retinal area just nasal to the optic disc (used for fixation) Pronounced mid and far-peripheral nummular intraretinal pigmentation (24yrs)	Eyepoking Enophthalmos Esotropia SCP Cataract (complete, OS)
<a href="#">CRBI</a> <a href="#">p.Trp1293X</a> <a href="#">+Trp1293X</a>	LCA-42	F		+	Absent (2yrs)		White retinal spots Salt and pepper pigmentation Maculopathy (2yrs)	Keratoconus Cataract (OD)
<a href="#">CRBI</a> <a href="#">p.Cys948Tyr</a> <a href="#">+Lys801X</a>	EORD-1 II-1	F	+	-	CRD		Optic disc pallor Retinal vessel attenuation Salt and pepper alterations Nummular intraretinal pigmentation (over 360°) No maculopathy	
	EORD-1 II-2	M	+	Mild	CRD		Optic disc pallor Salt and pepper alterations No maculopathy	
<a href="#">CRBI</a> <a href="#">p.Cys948Tyr</a> <a href="#">+Cys310Tyr</a>	EORD-2	M					Optic disc pallor Peripheral nummular intraretinal pigmentation No maculopathy	Cataract

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
<i>CRBI</i> <a href="#">p.[Cys948Tyr]</a> <a href="#">+.[Asp491Val]</a>	EORD-3	F	+	Strong	Absent		Hyperaemic optic disc Retina vessel attenuation Midperipheral pigment alterations Pseudopapilledema Bull's maculopathy (4yrs)	
<i>CRBI</i> <a href="#">p.[Gln362X]</a> <a href="#">(+).Gln362X]</a>	EORD-4	M			Absent		Peripheral nummular intraretinal pigmentation No maculopathy	Cataract
<i>CRBI</i> <a href="#">p.[Arg764Cys]</a> <a href="#">(+).Arg764Cys</a> 1	EORD-5	F	+	-	Absent	Normal	Pseudopapilledema Maculopathy (edema) Coats reaction (OD) Mid-peripheral spicular intraretinal pigmentation Excavation optic disc (OS)	SCP Cataract (OD) Glaucoma
<i>RPE65</i> <a href="#">p.[Arg44Gln]</a> <a href="#">+.[Arg44Gln]</a>	LCA-43	F	Strong	-	Absent	R/B (not R/Y)	Discrete retinal vessel attenuation Normal fundus Very small white intraretinal flecks in mid- and far periphery No preretinal fibrosis (4yrs)	Esotropia
<i>RPE65</i> <a href="#">p.[Pro181Leu]</a> <a href="#">+.[Pro181Leu]</a> 1	LCA-44	M	+	-	Absent	Disturbed	Retinal vessel attenuation Discrete RPE alterations (5mo) Optic disc pallor Retinal vessel attenuation Mild thinning of inferior retina Limited midperipheral intraretinal pigmentation Well-preserved macula (7yrs)	
<i>RPE65</i> <a href="#">p.[Arg234X]</a> <a href="#">+.[Trp331dup]</a> (LCA-45a)	LCA-45a	F					Optic disc pallor Depigmentations and round hyperpigmentations	
<i>RPE65</i> <a href="#">p.[Trp331dup]</a> <a href="#">+.[Trp331dup]</a> 1 (LCA-45b)	LCA-45b							

42 Coppieters et al.

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
<i>RPE65</i> <a href="#">p.Leu341Ser</a> <a href="#">p.Ser121Leuf</a> <a href="#">sX6 (de novo)</a>	LCA-46	F					Retinal vessel attenuation Limited but clear peripheral outer retinal atrophy No intraretinal pigmentation Relative preservation of essentially normal macula (21 yrs)	
<i>RPE65</i> <a href="#">p.[Phe530LeufsX40]+[Phe530]LeufsX40]</a>	LCA-47	M	+	- (searches for light)	Absent (9mo & 9yrs)	G/B R/0/P	Optic disc pallor Retinal vessel attenuation No pigmentation (5yrs) Normal optic discs Retinal vessel attenuation Discrete retinal thinning Cellophane maculopathy Limited macular pigment alterations Peripheral hypopigmentation Small discrete peripheral white flecks Total absence of AF (9yrs)	Eyepoking Cataract (very limited posterior lens opacification) Semimydrasis (ODS)
<i>RPE65</i> <a href="#">p.[Phe530LeufsX40]+[Arg124X]</a>	LCA-48	M			Absent (4mo & 1yr)	Basic	Optic disc pallor Retinal vessel attenuation Outer retinal atrophy especially in inferior midperiphery Relative sparing of the macula. Mild preretinal macular fibrosis	
<i>RPE65</i> <a href="#">p.[Phe530LeufsX40]+[Splice defect]</a>	LCA-49	M	Strong	- (searches for light)	Absent (1.9yrs)	Basic	Retinal vessel attenuation No pigment alterations Normal macula (1yr & 4.3yrs) Peripheral pigment alterations (6yrs) Normal optic disc Limited retinal vessel attenuation Peripheral RPE alterations without intraretinal pigment Very limited foveal pigment alterations	Semimydrasis
<i>RPE65</i> <a href="#">p.[Arg296LysfsX7]+[Splice defect]</a>	LCA-50	F			Absent (5mo)		Normal vessels Mild RPE alterations No hyperpigmentation Normal macula	Esotropia Hypertropia

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
<i>GUCY2D</i> <a href="#">p.[Pro130LeufsX36(+)]Splice defect]</a>	LCA-51	M			Absent (11mo & 3yrs)		Normal fundus	Eyepoking
<i>GUCY2D</i> <a href="#">p.[Phe565Ser(+)]Phe565Ser]</a>	LCA-52	M			Absent (6mo)		Normal fundus	Eyepoking Enophthalmos
<i>GUCY2D</i> <a href="#">p.[Arg768Trp(+)]Arg768Trp]</a>	LCA-53	M						
<i>GUCY2D</i> <a href="#">p.[Arg768Trp(+)]Phe565Ser]</a>	LCA-54	F	+ (since early age)	+ (since the age of 2.6)	Absent (3mo)		Normal fundus (1yr & 3.2yrs)	Eyepoking Enophthalmos Esotropia
<i>GUCY2D</i> <a href="#">p.[Arg768Trp(+)]Lys866Asn]</a>	LCA-55	M			Absent (4.4yrs)		Pseudopapilledema Essentially normal fundus Limited peripheral salt and pepper alterations Limited hyperAF of the central macula (13yrs)	Eyepoking
<i>GUCY2D</i> <a href="#">p.[Glu196Val(+)]Pro711Leu1]</a>	LCA-56	F	-	Strong	Absent (3mo)	Basic Strong R/G and B/Y defect	Optic disc pallor Retinal vessel attenuation Limited peripheral outer retinal atrophy No intraretinal pigmentation Normal macula Foveolar yellowish atrophy No hyper- or hypoAF (25yrs)	Eyepoking Enophthalmos Esotropia Keratoconus with acute hydrops (OD>OS) (16yrs)
<i>GUCY2D</i> <a href="#">p.Pro575Leu]</a>	LCA-57	F	+		Absent (3.3yrs)	Severely disturbed	Optic disc hypoplasia Bull's maculopathy	
<i>AIP1</i> <a href="#">p.[Trp278X(+)]Trp278X]</a>	LCA-58 (Yzer, Leroy et al. 2006)	F		Mild	Absent (3mo & 1yr)		Bull's eye maculopathy, diffuse RPE alterations; limited intraretinal pigment migration of spicular type; sub- or deep intraretinal fine white deposits predominantly along vascular arcades	
<i>AIP1</i> <a href="#">p.[Trp278X(+)]Trp278X]</a>	LCA-59	M		+ (since the age of 4.10)	Absent (2yrs)		Retinal vessel attenuation No intraretinal pigmentation Macular pigment alterations (5yrs)	Eyepoking

44 Coppieters et al.

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
<i>AIP1</i> p.[Trp278X] (+)[Trp278X]	LCA-60	M					Normal optic discs Retinal vessel attenuation Peripheral outer retinal atrophy Spicular intraretinal pigmentation Total outer retinal aplasia of central macula, surrounded by thin rim of hyperplastic RPE (28yrs)	
<i>AIP1</i> p.[Trp278X] + [Trp278X]	LCA-61	F	+	Strong (after first decade)	Absent (3mo & 6mo)		Limited optic disc pallor Retinal vessel attenuation Extensive outer retinal atrophy Mid and far-peripheral spicular pigmentation Better preserved macula with central yellow atrophy (19yrs)	Eyepoking Esotropia
<i>AIP1</i> p.[Thr114Ile; Pro376Ser]	LCA-62	F			Absent (1.4yrs)		Optic disc pallor Retinal vessel attenuation	Eyepoking
<i>CRX</i> p.[Tyr142Cys]	LCA-63	M			Absent (6mo)			Eyepoking
<i>CRX</i> p.[Val242Met]	LCA-64	M						
<i>RDH12</i> p.[Ala269Glyf sX2] +[Val233 Asp]	EORD-6	M					Optic disc pallor Retinal vessel attenuation Salt and pepper alterations	
<i>RDH12</i> p.[Ala269Glyf sX2] +[Ser175 Leu]	EORD-7	M	+(since early age)	+	Absent (3.5yrs)	Basic (5.10yrs)	Limited retinal vessel attenuation Better preservation of the chorioretina in the posterior pole than in the periphery Clear retinal pigment epithelium alterations Peripheral areas of preserved chorioretina alternating with areas of total atrophy with predominant spicular intraretinal pigmentation (5yrs) Retinal vessel attenuation Yellowish discoloration of central macula More prominent spicular intraretinal pigmentation Areas with complete preservation of peripheral chorioretina	Esotropia

Gene	Patient n°	Gender	Night Blindness	Photophobia	ERG	Color vision	Fundus aspect	Other features
							(19yrs)	
<i>RDH12</i> <a href="#">p.[Ala269GlyfsX2(+) Ala269GlyfsX21]</a>	EORD-8							
<i>RPGRI1</i> <a href="#">p.Arg890X</a>	LCA-65			Strong				

46 Coppieters et al.

Supplementary Table S3 – Part II

Gene	Patient n°	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features
				OD	OS	OD	OS					
<a href="#">CEP290</a> <a href="#">p.[Cys998X]+[Cys998X]</a>	LCA-1	M		LP?	LP?	+5	+5		Normal MRI			
<a href="#">CEP290</a> <a href="#">p.[Cys998X]+[Cys998X]</a>	LCA-2	M	+	20/600 (1yr & 5yrs)	20/600 (1yr & 5yrs)	+7	+7			-		
<a href="#">CEP290</a> <a href="#">p.[Cys998X]+[Arg108X]</a>	LCA-3	M	+	2/24 (6yrs)	2/24 (6yrs)	+7 (3mo) +8.25 (6yrs)	+7 (3mo) +8.25 (6yrs)		<u>MRI:</u> Broadened supertentorial ventricular system without signs of intracranial hypertension (11mo)	Mild MR Autism	RDI Daytime incontinence Normal kidney US (6.10yrs)	Growth retardation (length and weight) Prematurity (36w)
<a href="#">CEP290</a> <a href="#">p.[Cys998X]+[Gln899X]</a>	LCA-4	F	+	NLP (since birth)	NLP (since birth)					-		
<a href="#">CEP290</a> <a href="#">p.[Cys998X]+[Arg1465X]</a>	LCA-5	M		NLP (1.8yrs & 8yrs)	NLP (1.8yrs & 8yrs)	+6 (4mo)	+6 (4mo)		TDM brains: modest cortical atrophy with limited subdural bifrontal fluid collection (4mo) EEG: normal (4mo)			MEI
<a href="#">CEP290</a> <a href="#">p.[Cys998X]+[Lys1575X]</a>	LCA-6	F	+	1.5/24 (3.6yrs) 1/20 (18.5yrs)	3/36 (3.6yrs) 2/10 (18.5yrs)	+4 (18yrs)	+4 (18yrs)	Reduced	MRI: slightly broadened lateral ventricles (3.4yrs)	Learning disability	Normal kidney US, normal kidney function (3yrs)	

Deleted: CEP290

Deleted: CEP290

Deleted: NMR

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

Gene	Patient n°	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features
				OD	OS	OD	OS					
<a href="#">CEP290 p.[Cys99 8X(+)]Lys 1575X↓</a>	LCA-7	M	+	CF at 2m (21yrs) LP with incomplete loc (49yrs)	CF at 2m (21yrs) HM at 2m (49yrs)	+3.5 (42yrs)	+3.5 (42yrs)	30° (35yrs & 49yrs)		-		
<a href="#">CEP290 p.[Cys99 8X(+)]Lys 1575X↓</a>	LCA-8	F	+	1/60 (6yrs) HM 2m (30yrs)	1/36 (6yrs) HM 1.5m (30yrs)	+5	+5	5°		-		
<a href="#">CEP290 p.[Cys99 8X(+)]Arg 1782X↓</a>	LCA-9	M	+	1/20 (6yrs)	1/20 (6yrs)	+2.25	+2.25	10° (6yrs)	Normal MRI	-		
<a href="#">CEP290 p.[Cys99 8X(+)]Asp 128Glufs X17↓</a>	LCA-10	F	+	NLP	NLP	+4	+4		Normal MRI (10yrs)	-	Normal kidney US (10yrs)	Obesity
<a href="#">CEP290 p.[Cys99 8X(+)]Glu 146Glyfs X17↓</a>	LCA-11	M	REM	NLP	NLP	+8	+8		Normal MRI	-		
<a href="#">CEP290 p.[Cys99 8X(+)]Arg 621IlefsX 2↓</a>	LCA-12	M	+	NLP	NLP	+10 (6mo)	+10 (6mo)			-	Normal kidney US (1yr)	
<a href="#">CEP290 p.[Cys99 8X(+)]Leu 1141Phefs sX5↓</a>	LCA-13	F		NLP	NLP	+8	+8		Normal CT scan MRI: 2 atypical white matter lesions (17yrs – 19yrs)	MR Epilepsy		
<a href="#">CEP290 p.[Cys99 8X(+)]Thr 1334Ilefs X2↓</a>	LCA-14	F	+	LP? (7mo) NLP (7.8yrs)	LP? (7mo) NLP (7.8yrs)				MRI: slightly broadened lateral ventricles (5mo)	-		Limited ventricle septum defect (VSD): slow

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

48 Coppieters et al.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Gene	Patient n°	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features
				OD	OS	OD	OS					
												closure, Asthma Familial palatoschisis Brother died from SIDS
<a href="#">CEP290 p.[Cys99 8X(+)]Glu 1656Asnf sX3↓</a>	LCA-15 (Perrault, Delphin et al. 2007)	M	+	LP	LP	Hypermetria hypermetropic (strong)	Hypermetria hypermetropic (strong)		Normal MRI (1.3yrs)	Dev del- Autism?		Discrete scoliosis
<a href="#">CEP290 p.[Cys99 8X]+[Ala 1832Profs X19↓</a>	LCA-16	M	+	NLP	NLP	+8	+8			-		Obesitas
<a href="#">CEP290 p.[Cys99 8X]+[Lvs 1840Argf sX5↓</a>	LCA-17	M	+	LP No loc	LP No loc	+7	+7			Autism Normal IQ		Carrier of a non-pathogenic translocation : 45,XY,t(13;14) (father has the same)
<a href="#">CEP290 p.[Cys99 8X]+[Glu 1956Glyf sX9↓</a>	LCA-18	M	+	LP No loc (early in life)	LP No loc (early in life)			Conc constr	Normal CT scan (5mo)	Non-verbal learning disability Ataxia (Mild) Dyspraxia (10yrs) Balance and coordination problems	Normal kidney US (5mo)	
<a href="#">CEP290 p.[Cys99 8X]+[Do nor</a>	LCA-19	M	+	NLP (since birth)	NLP (since birth)				<a href="#">MRI</a> : Frontal and temporal cortical atrophy	Autism Mild-moderate MR	Normal kidney US (6mo)	

Field Code Changed

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

Deleted: NMR

Gene	Patient n°	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features
				OD	OS	OD	OS					
<a href="#">Splice defect</a>										Verbal IQ = 55 Coordination problems		
<a href="#">CEP290 p.[Cys99 8X(+)]Acc eptor Splice defect</a>	LCA-20 (Yzer, Leroy et al. 2006)	F	+	< 1/20 (45yrs) NLP (54yrs)	< 1/20 (45yrs) NLP (54yrs)					Severe MR		Meningitis (6w)
<a href="#">CEP290 p.[Cys99 8X(+)]Acc eptor splice defect</a>	LCA-21	M	+	LP	LP	+5	+5		Normal CT scan	Mild MR ADHD Movement abnormalities		Chrom dupl 14q24-32.3 (< mother: carrier of a balanced translocation)
<a href="#">CEP290 p.[Cys99 8X(+)]Acc eptor Splice defect</a>	LCA-22	M	-	LP	LP					-		
<a href="#">CEP290 p.[Cys99 8X(+)]Acc eptor Splice defect</a>	LCA-23	F	+	LP?	LP?				(1.2yrs)	Severe MR Dev Del Epilepsy Axial hypotonia (mild)	Kidney US: hyperdensity (3yrs) No other signs of NPHP (17yrs)	Hyperlax ligaments Hyperlordosis
<a href="#">CEP290 p.[Lys157 5X(+)]Lys 157X</a>	LCA-24	M								Severe MR		
<a href="#">CEP290</a>	LCA-25	M	+	20/600	20/600	+3.5	+3.5	10°- 15°	Normal MRI	-		

Deleted: CEP290

Field Code Changed

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

50 Coppieters et al.

Gene	Patient n°	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features
				OD	OS	OD	OS					
<a href="#">p.[Lys1575X]+[Ala1566Pro]</a>				(9mo) 1/60 (5yrs)	(9mo) 1/24 (5yrs)	(9yrs)	(9yrs)	paracentral	(4mo)			
<a href="#">CEP290 p.[Leu1694Pro]+[=,splice site]</a>	LCA-26		+	5/60 (3yrs) 1/10 (4.5yrs)	5/60 (3yrs) 1/10 (4.5yrs)	+3.25 (4.5yrs)	+3 (4.5yrs)					
<a href="#">CEP290 p.Cys998X</a>	LCA-27	M	+	0.16	0.16			50°		-		
<a href="#">CEP290 p.[Trp7Cys]+[Trp7Cys]</a>	SLS-1	F	+	No reaction on light (2mo)	No reaction on light (2mo)	>+4	>+4		-?	No ataxia/hypotonia	UTI RDI CKD5 (5yrs) RTx (6yrs)	Glue ear Clinodactyly Sibling died shortly after birth (enlarged kidneys; chrom 6 defect)
<a href="#">CEP290 p.[Lys1575X(+)+Arg1465X]</a>	SLS-2	F	+	LP with loc	LP with loc			<20° (14yrs)	Broadened 4th ventricle	Mild MR Balance problems	<a href="#">Diagnosis renal insufficiency (30yrs)</a> RDI Peritoneal dialysis (34yrs) <a href="#">Kidney transplant (34yrs)</a>	Syncopes Scoliosis
<a href="#">CEP290 p.[Lys1575X(+)+Arg1465X]</a>	SLS-3	M		NLP	NLP					Moderate MR Severe autism Mild ataxia	RDI (7yrs) Kidney US: hyperden-sity (13yrs)	Recurrent OM

Deleted: CEP290

Deleted: CEP290

Deleted: [

Deleted: (+)?]

Deleted: CEP290

Deleted: CEP290

Comment [FC1]: Correcte leeftijden toevoegen

Deleted: CEP290

Deleted: CEP290



Gene	Patient n°	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features
				OD	OS	OD	OS					
											CKD5 (16yrs) <a href="#">Peritoneal dialysis (since the age of 17)</a>	
<a href="#">CEP290</a> <a href="#">p.[Lys1575X(+)]Arg1465X↓</a>	CORS-1 (Brancati, Barrano et al. 2007)	F	+	LP with loc	LP with loc	+10, +12	+10, +12		+	Severe MR Ataxia Balance problems	RDI (6yrs) Kidney US: hyperdensity (6yrs) CKD5 (14yrs) Deceased (16yrs)	Scoliosis Recurrent OM Congenital chylothorax Alternating tachypnea Syncope
<a href="#">CEP290</a> <a href="#">p.[Gln1265X]+[Aceptor splice defect]</a>	LCA-JS-1	M	+	1/100	1/100	+5	+5	tubular	+ (4yrs)	Hypotonia Walking problems		
<a href="#">CEP290</a> <a href="#">p.[Thr2457AlafsX27]+[Thr2457AlafsX27]</a>	LCA-JS-2 II-1	F	+	1.5/10	1/10	+5	+5	10°	+	Walking problems		
	LCA-JS-2 II-2	A	+	1/20	1/20	+4.5	+3.5	10°	+	Mild MR Walking problems		
<a href="#">CEP290</a> <a href="#">p.[Leu2448ThrfsX8(+)]Acceptor splice defect</a>	LCA-JS-3	M	REM	NLP (since birth)	NLP (since birth)				?	Severe psychomotor retardation Hypotonia No ataxia	Normal kidney US (1yr)	Scoliosis
<a href="#">CRB1</a> <a href="#">p.[Lys801</a>	LCA-28	M		1/100	1/100							

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

Deleted: CEP290

52 Coppieters et al.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Gene	Patient n°	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features
				OD	OS	OD	OS					
<a href="#">X(+Lys801X)</a>												
<a href="#">CRB1 p.[Lys801X(+Gln362X)]</a>	LCA-29 (Yzer, Leroy et al. 2006)	M	+	20/600 (1yr) 1/30 (7.9yrs) 1/40 (25 yrs)	20/600 (1yr) <1/50 (7.9yrs) 1/40 (25 yrs)	+2.25 (30.6yrs) (astigm)	+1.88 (30.6yrs) (astigm)	OD: central residual visual field, OS: temporal inferior and partially superior visual field intact (30.6yrs)				
<a href="#">CRB1 p.[Lys801X]+[Arg764Cys]</a>	LCA-30	M										
<a href="#">CRB1 p.[Lys801X]+[Cys896X]</a>	LCA-31 (Yzer, Leroy et al. 2006)	M	+	HM on 20 cm (3mo & 6yrs)	HM on 20 cm (3mo & 6yrs)	+10	+9.5					
<a href="#">CRB1 p.[Lys801X(+Cys896X)]</a>	LCA-32 (Yzer, Leroy et al. 2006)	F	+	1/100 (1yr) <1/600 (35yrs)	1/100 (1yr) <1/600 (35yrs)	+4 (19yrs)	+4 (19yrs)	40°; remaining temporal crescent (19yrs)				Asthma Torticollis (to the left)
<a href="#">CRB1 p.[Lys801X(+Cys948Tyr)]</a>	LCA-33	F	+	CF at 1m (until 8yrs) HM at 0.5m (9yrs)	CF at 1m (until 8yrs) CF at 10cm (9yrs)	+4	+4	10°				
<a href="#">CRB1 p.[Lys801X]+[Acce]</a>	LCA-34	F	+	20/800 (1.11yrs)	20/800 (1.11yrs)	+5	+5	Remainng island in				

Deleted: CRB1

Field Code Changed

Deleted:

Deleted: CRB1

Deleted: ¶

Deleted: CRB1

Field Code Changed

Deleted: CRB1

Field Code Changed

Deleted:

Deleted: CRB1

Deleted: CRB1

Gene	Patient n°	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features
				OD	OS	OD	OS					
<a href="#">ptor splice defect↓</a>								peripheral field				
<a href="#">CRB1 p.[Cys94 8Tyr(+)]Cys948Tyr↓</a>	LCA-35	F		LP	LP							
<a href="#">CRB1 p.[Cys94 8Tyr(+)]Glu1330X↓</a>	LCA-36	F	+	LP	LP					-		
<a href="#">CRB1 p.[Cys94 8Tyr]+[Splice defect↓]</a>	LCA-37	M	+	LP (decreased since the age of 13)	LP (decreased since the age of 13)				Normal CT scan	-		
<a href="#">CRB1 p.[Cys94 8Tyr]+[Splice defect↓]</a>	LCA-38	M	+	0.07 LP with localisation (17yrs)	0.07 LP with localisation (17yrs)	+9	+9	10°	Normal CT scan (5.9yrs)	-		
<a href="#">CRB1 p.[Cys94 8Tyr]+[Splice defect↓] (LCA-39a) and p.[Splice defect]+[Splice defect↓] (LCA-39b)↓</a>	LCA-39a	F	+	1.5/36 (4.9yrs) HM 1m (15.11yrs)	2/36 (4.9yrs) HM 1m (15.11yrs)	+4.75	+5.25	10°		-		
	LCA-39b	M		0.08	0.08			10°-20°		-		
<a href="#">CRB1 p.[Splice defect(+)]</a>	LCA-40	M	+	0.08 (3yrs) LP	0.08 (3yrs) NLP			<10°	Normal CT scan	-		

Deleted: CRB1

Deleted: CRB1

Deleted: CRB1

Deleted: CRB1

Deleted: CRB1

Deleted: CRB1

54 Coppieters et al.

Gene	Patient n°	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features
				OD	OS	OD	OS					
<a href="#">Splice defect↓</a>				(22 yrs)	(22 yrs)							
<a href="#">CRBI p.[Leu814ArgfsX23]+[Cys1240ProfsX24]↓</a>	LCA-41 II-1	F	+	3/10 (8yrs) CF at 15cm (37yrs)	3/10 (8yrs) CF at 15cm (37yrs)	+9	+9	30-50°		-		
	LCA-41 II-2	F	+	1/20 (14yrs) 1/20 (28yrs)	1/100 (14yrs) CF at 50cm (28yrs)	+4.5 Astigm	+1.5 Astigm	50-60° horizontally 70° vertically		-		
<a href="#">CRBI p.[Trp1293X(+)]Trp1293X↓</a>	LCA-42	F		2/10 (2yrs) LP	4/10 (2yrs) LP	+5	+5	10°		-		
<a href="#">CRBI p.[Cys948Tyr]+[Lys801X]↓</a>	EORD-1 II-1	F	-	1/50	1/50	+6	+6	60°		-		
	EORD-1 II-2	M		1/50	1/20	+3	+3	10°		-		
<a href="#">CRBI p.[Cys948Tyr(+)]Cys310Tyr↓</a>	EORD-2	M		LP	NLP	+	+	10°		-		
<a href="#">CRBI p.[Cys948Tyr]+[Asp491Val]↓</a>	EORD-3	F	+	2/10 (4yrs) 1/20 (11.9yrs)	2/10 (4yrs) 1/20 (11.9yrs)	+4.5 (10.10yrs)	+4.5 (10.10yrs)	Complete (4yrs) 15°-30° (11yrs)	MRI: subcortical white matter lesions, frontal (right) in centrum semi-ovale	Learning disability (but normal IQ)		
<a href="#">CRBI p.[Gln362X(+)]Gln362X↓</a>	EORD-4	M	+	3/10 (16yrs) LP	3/10 (16yrs) LP	+6	+6	10°		-		
<a href="#">CRBI p.[Arg764Cys(+)]A</a>	EORD-5	F	-	5/10 (until 5yrs) LP no loc	7/10 (until 5yrs) HM	+2D (12yrs) +5D	+3D (12yrs) +5D	30° (12yrs) Absent		-	Normal kidney US	

Deleted: CRBI

Deleted: CRBI

Deleted: CRBI

Deleted: CRBI

Deleted: CRBI

Deleted: CRBI

Deleted: CRBI

Gene	Patient n°	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features
				OD	OS	OD	OS					
<a href="#">rg764Cys</a> ↓				(18.4yrs)	(18.4yrs)			(19yrs)				
<a href="#">RPE65 p.[Arg44Gln]+[Arg44Gln]</a> ↓	LCA-43	F	+	1/20	1/20	+4.5 (7mo)	+4.5 (7mo)	Conc constr	Normal MRI	MR Autism		Obesitas
<a href="#">RPE65 p.[Pro181Leu]+[Pro181Leu]</a> ↓	LCA-44	M	+	1/10 (4yrs & 9yrs)	3/10 (4yrs & 9yrs)	-6	-6		Normal CT scan and EEG (5mo)	Behavioural anomalies	Normal kidney US (2yrs)	Mild perceptive hearing loss (Cx26 negative)
<a href="#">RPE65 p.[Arg234X]+[Trp331dup] (LCA-45a) and p.[Trp331dup]+[Trp331dup] (LCA-45b)</a>	LCA-45a LCA-45b	F		<1/20	<1/20							
<a href="#">RPE65 p.Leu341Ser p.Ser121LeufsX6 (de novo)</a>	LCA-46	F										
<a href="#">RPE65 p.[Phe530LeufsX40]+[Phe530LeufsX40]</a> ↓	LCA-47	M	+	1/10 (5yrs) 5/100 (9yrs)	1/10 (5yrs) 5/100 (9yrs)	+4 (9yrs)	+4.5 (9yrs)	Moderate conc constr		Attention deficit disorder		
<a href="#">RPE65 p.[Phe530LeufsX40]+[Arg12]</a>	LCA-48	M	+	15/100 (5yrs) 2/10 (10yrs)	12/100 (5yrs) 2/10 (10yrs)	-2.25	-2.5	40°		-		

Deleted: CRB1

Deleted: RPE65

Deleted: RPE65

Deleted: RPE65

Deleted: RPE65

Deleted: RPE65

56 Coppieters et al.

Gene	Patient n°	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features
				OD	OS	OD	OS					
<del>4X1</del>												
<del>RPE65 p.[Phe530LeufsX40][+Splice defect]</del>	LCA-49	M	+ (compensatory head movements)	< 0.035 (4.3yrs) 1/60 (10yrs)	0.1 (4.3yrs) 1/20 (10yrs)	+1.5 (20mo) +2.6 (10yrs)	+2.5 (20mo) +1 (10yrs)	Moderate conc constr	Normal MRI (9mo)	-		
<del>RPE65 p.[Arg296LysfsX7][+Splice defect]</del>	LCA-50	F	+	1/10 (3yrs)	1/10 (3yrs)	+5 (8mo)	+5.75 (8mo)		Normal MRI (7mo)			
<del>GUCY2D p.[Pro130LeufsX36(+)]Splice defect]</del>	LCA-51	M	+	NLP	NLP							
<del>GUCY2D p.[Phe565Ser(+)]Phe565Ser]</del>	LCA-52	M	+	LP	LP	+4	+4		Normal MRI	-	US: hydro-ureteronephrosis	
<del>GUCY2D p.[Arg768Trp(+)]Arg768Trp]</del>	LCA-53	M										
<del>GUCY2D p.[Arg768Trp][+Phe565Ser]</del>	LCA-54	F	+	1/600 (4.9yrs)	1/120 (4.9yrs)	+3.75 (4.7yrs)	+4.25 (4.7yrs)	Constricted (2.6yrs)		-		
<del>GUCY2D p.[Arg768Trp][+Lys866Asn]</del>	LCA-55	M	+	LP	LP	+9	+9	10°		MR autism		
<del>GUCY2D p.[Glu196Val][+Pro711Leu]</del>	LCA-56	F	+	1/30 (5.5yrs) 3/100 (23yrs)	1/30 (5.5yrs) 3/100 (23yrs)	+6	+6	Moderate conc constr		-		
<del>GUCY2D</del>	LCA-57	F	+	6/60	6/36	-6	-6		MRI: hypoplasia	MR		

Deleted: RPE65

Deleted: RPE65

Deleted: RPE65

Deleted: GUCY2D

Deleted: GUCY2D

Deleted: GUCY2D

Deleted: GUCY2D

Deleted: GUCY2D

Deleted: GUCY2D

Gene	Patient n°	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features
				OD	OS	OD	OS					
<a href="#">p.Pro575 Leu</a>									optic nerves			
<a href="#">AIPL1</a> <a href="#">p.[Trp278 X]+[Trp278X]</a>	LCA-58 (Yzer, Leroy et al. 2006)	F		<20/600 (3yrs) 1/50 (8 yrs)	<20/600 (3yrs) 1/50 (8 yrs)	+8	+8		Normal CT scan			
<a href="#">AIPL1</a> <a href="#">p.[Trp278 X (+)[Trp278X]</a>	LCA-59	M	+	<1/50 (2yrs) 1/100 (4.10yrs)	<1/50 (2yrs) 1/100 (4.10yrs)	+3.5D (2.5yrs)	?		Normal CT scan (6mo)	Mild Developmental delay		
<a href="#">AIPL1</a> <a href="#">p.[Trp278 X (+)[Trp278X]</a>	LCA-60	M										
<a href="#">AIPL1</a> <a href="#">p.[Trp278 X]+[Trp278X]</a>	LCA-61	F	+	<1/100 (7yrs) LP with limited loc (21yrs)	<1/100 (7yrs) LP with limited loc (21yrs)	+6	+6	20° (7yrs) Residual pericentral remnants (21yrs)	Normal CT scan (10mo)	-		
<a href="#">AIPL1</a> <a href="#">p.[Thr114 Ile: Pro376Ser]</a>	LCA-62	F	+	1/10	1/10				Normal MRI	-		
<a href="#">CRX</a> <a href="#">p.Tyr142 Cys</a>	LCA-63	M	+	LP	LP	+9	+9			-		
<a href="#">CRX</a> <a href="#">p.Val242 Met</a>	LCA-64	M										
<a href="#">RDH12</a> <a href="#">p.[Ala269 GlyfsX2] +[Val233]</a>	EORD-6	M	-	5/10 (4yrs) 1/10 (23yrs)	5/10 (4yrs) 1/10 (23yrs)			30° (8yrs) 5° (12yrs)	Normal CT scan	-		

Deleted: GUCY2D

Field Code Changed

Deleted: AIPL1

Deleted: AIPL1

Deleted: AIPL1

Deleted: AIPL1

Deleted: AIPL1

Deleted: ¶  
(no date)

Deleted: ¶  
(no date)

Deleted: CRX

Deleted: CRX

58 Coppieters et al.

Gene	Patient n <sup>o</sup>	Gender	Nyst	BCVA (age)		Refraction (age)		VF	MTS	Neurologic Features	Kidney	Other Features	
				OD	OS	OD	OS						
<a href="#">Aspl</a>													Deleted: RDH12
<a href="#">RDH12</a> <a href="#">p.[Ala269GlyfsX2]</a> <a href="#">+[Ser175Leu]</a>	EORD-7	M	+	3/9 (3.5yrs) HM (19yrs)	3/9 (3.5yrs) 1.5/10 (19yrs)			OD: temporal crescent, OS: 70° (6yrs) OD: status- quo OS: central 5° (19.3yrs)		-			Deleted: RDH12
<a href="#">RDH12</a> <a href="#">p.[Ala269GlyfsX2(+Ala269GlyfsX2)]</a>	EORD-8	M		4/10	4/10			10°					Deleted: RDH12
<a href="#">RPGRIP1</a> <a href="#">p.Arg890X</a>	LCA-65	M		1/10	1/10			10°					Deleted: RPGRIP1

Supplementary Table S3: Clinical data of 80 patients with mutation(s) in one of the LCA genes.

If available, the age of the first and last measurement is mentioned between brackets. A question mark indicates an uncertain status. [Blank fields indicate features for which no information could be obtained.](#) Clinical data on the two patients included in the Phase I clinical trial for *RPE65* gene-replacement therapy (LCA-47 and LCA-49) concern the period preceding therapy. Characteristics described in "Other features" are binocular, if not mentioned otherwise.

Abbreviations used: N<sup>o</sup>, number; cons, consanguinity; nyst, nystagmus; BCVA, best corrected visual acuity; OD, right eye; OS, left eye; ODS, both eyes; ERG, electroretinogram; VF, visual field; MTS, molar tooth sign; [MRI, magnetic resonance imaging](#); MR, mental retardation; NPHP, nephronophthisis; SE, spherical equivalent; +, present; -, absent; yr(s), year(s); mo, month(s); W, week(s); REM, roving eye movements; HM, hand motion; LP, light perception; NLP, no light perception; CF, counting fingers; AF, autofluorescence; OCT, optical coherence tomography; US, ultrasound; SIDS, sudden infant death syndrome; conc constr, concentrically constricted; G, green; B, blue; R, red; O, orange; P, pink; RPE, retinal pigment epithelium; PPRPE, preserved para-arteriolar retinal pigment epithelium; astigm, astigmatism; loc, localization; CRD: cone-rod dystrophy; SCP: subcapsularis posterior; dev del: developmental delay; MEI: middle ear infections; RDI: renal diabetes insipidus; CKD5: renal failure; RTx: transplantation.

1			
2			
3	<b>Page 5: [1] Deleted</b>	<b>UGent</b>	<b>4/8/2010 2:06:00 PM</b>
4	,		
5			
6	<b>Page 5: [1] Deleted</b>	<b>UGent</b>	<b>4/8/2010 2:06:00 PM</b>
7	In three of them, two heterozygous variants were detected in two genes, respectively. The other one		
8	carried a homozygous variant in one gene together with a heterozygous variant in another gene.		
9			
10	<b>Page 5: [2] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:23:00 PM</b>
11	For one patient, t		
12			
13	<b>Page 5: [2] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:23:00 PM</b>
14	the mutation		
15			
16	<b>Page 5: [3] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:23:00 PM</b>
17	(		
18			
19	<b>Page 5: [3] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:23:00 PM</b>
20	, <i>CRBI</i> p.Glu1330X)		
21			
22	<b>Page 5: [3] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:24:00 PM</b>
23	of the LCA chip		
24			
25	<b>Page 5: [4] Deleted</b>	<b>UGent</b>	<b>4/8/2010 2:13:00 PM</b>
26	on the LCA chip		
27			
28	<b>Page 5: [4] Deleted</b>	<b>UGent</b>	<b>4/8/2010 2:17:00 PM</b>
29	direct		
30			
31	<b>Page 5: [5] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 11:28:00 AM</b>
32	considered		
33			
34	<b>Page 5: [5] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 11:28:00 AM</b>
35	using LCA chip analysis		
36			
37	<b>Page 5: [6] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:17:00 PM</b>
38	As a second step		
39			
40	<b>Page 5: [6] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 11:29:00 AM</b>
41	complete		
42			
43	<b>Page 5: [6] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 11:30:00 AM</b>
44	a		
45			
46	<b>Page 5: [6] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 11:30:00 AM</b>
47	analysis		
48			
49	<b>Page 5: [6] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 2:02:00 PM</b>
50	Sanger		
51			
52	<b>Page 5: [7] Deleted</b>	<b>UGent</b>	<b>4/8/2010 2:25:00 PM</b>
53	LCA		
54			
55	<b>Page 5: [7] Deleted</b>	<b>UGent</b>	<b>4/8/2010 2:25:00 PM</b>
56			
57			
58			
59			
60			

1  
2  
3 all

4  
5 **Page 5: [7] Deleted** **UGent** **4/8/2010 2:22:00 PM**

6 in the entire LCA cohort

7  
8 **Page 5: [7] Deleted** **UGent** **4/8/2010 2:24:00 PM**

9 identified in *CEP290*-related LCA

10  
11 **Page 5: [8] Deleted** **UGent** **4/8/2010 2:41:00 PM**

12 ,

13  
14 **Page 5: [8] Deleted** **UGent** **4/8/2010 2:41:00 PM**

15 LCA-25

16  
17 **Page 5: [8] Deleted** **UGent** **4/8/2010 2:41:00 PM**

18 , LCA-26

19  
20 **Page 5: [9] Deleted** **Frauke Coppieters** **4/16/2010 1:00:00 PM**

21 Table 2

22  
23 **Page 5: [9] Deleted** **Frauke Coppieters** **6/16/2010 11:33:00 AM**

24 that

25  
26 **Page 5: [10] Deleted** **UGent** **4/8/2010 2:27:00 PM**

27 several

28  
29 **Page 5: [10] Deleted** **UGent** **4/8/2010 2:28:00 PM**

30 three SLS, three LCA-JS and one CORS

31  
32 **Page 5: [10] Deleted** **UGent** **4/8/2010 1:51:00 PM**

33 Five

34  
35 **Page 5: [10] Deleted** **UGent** **4/8/2010 2:28:00 PM**

36 harboured

37  
38 **Page 5: [10] Deleted** **UGent** **4/8/2010 2:29:00 PM**

39 in one family,

40  
41 **Page 5: [10] Deleted** **UGent** **4/8/2010 2:36:00 PM**

42 with the disease

43  
44 **Page 5: [10] Deleted** **UGent** **4/8/2010 2:29:00 PM**

45 (

46  
47 **Page 5: [10] Deleted** **UGent** **4/8/2010 2:29:00 PM**

48 )

49  
50 **Page 5: [11] Deleted** **UGent** **4/8/2010 1:52:00 PM**

51 In two patients, s

52  
53 **Page 5: [11] Deleted** **UGent** **4/8/2010 1:52:00 PM**

54 (

1			
2			
3	<b>Page 5: [11] Deleted</b>	<b>UGent</b>	<b>4/8/2010 1:52:00 PM</b>
4	and LCA-JS-3)		
5			
6	<b>Page 5: [11] Deleted</b>	<b>UGent</b>	<b>4/8/2010 1:52:00 PM</b>
7	in two other patients,		
8			
9	<b>Page 5: [11] Deleted</b>	<b>UGent</b>	<b>4/8/2010 1:52:00 PM</b>
10	(		
11			
12	<b>Page 5: [11] Deleted</b>	<b>UGent</b>	<b>4/8/2010 1:53:00 PM</b>
13	)		
14			
15	<b>Page 5: [11] Deleted</b>	<b>UGent</b>	<b>4/8/2010 1:53:00 PM</b>
16			
17			
18	<b>Page 5: [11] Deleted</b>	<b>UGent</b>	<b>4/8/2010 1:53:00 PM</b>
19	three of these patients		
20			
21	<b>Page 5: [12] Deleted</b>	<b>Frauke Coppiters</b>	<b>6/16/2010 11:35:00 AM</b>
22	), a novel mutation (		
23			
24	<b>Page 5: [12] Deleted</b>	<b>Frauke Coppiters</b>	<b>4/16/2010 1:00:00 PM</b>
25	Table 2		
26			
27	<b>Page 5: [12] Deleted</b>	<b>Frauke Coppiters</b>	<b>6/16/2010 11:37:00 AM</b>
28	whole		
29			
30	<b>Page 13: [13] Deleted</b>	<b>UGent</b>	<b>4/8/2010 3:56:00 PM</b>
31	nine		
32			
33	<b>Page 13: [13] Deleted</b>	<b>UGent</b>	<b>4/8/2010 3:56:00 PM</b>
34	seven		
35			
36	<b>Page 13: [13] Deleted</b>	<b>UGent</b>	<b>4/8/2010 3:55:00 PM</b>
37	, 26 of which were novel		
38			
39	<b>Page 13: [14] Deleted</b>	<b>UGent</b>	<b>4/8/2010 3:51:00 PM</b>
40	Mutations were identified in 69% (63/91) of probands, with an established diagnosis - two mutations		
41	found - in 65% (59/91).		
42			
43	<b>Page 13: [14] Deleted</b>	<b>UGent</b>	<b>4/8/2010 3:56:00 PM</b>
44	,		
45			
46	<b>Page 13: [14] Deleted</b>	<b>UGent</b>	<b>4/8/2010 3:56:00 PM</b>
47	five of which were novel mutations		
48			
49	<b>Page 13: [15] Deleted</b>	<b>Frauke Coppiters</b>	<b>4/16/2010 2:44:00 PM</b>
50	43		
51			
52	<b>Page 13: [15] Deleted</b>	<b>Frauke Coppiters</b>	<b>4/16/2010 2:44:00 PM</b>
53	9		
54			
55	<b>Page 13: [15] Deleted</b>	<b>Frauke Coppiters</b>	<b>4/16/2010 2:46:00 PM</b>
56			
57			
58			
59			
60			

6

<b>Page 13: [15] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 5:18:00 PM</b>
------------------------------	--------------------------	-----------------------------

all patients of this study

<b>Page 13: [16] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 6:38:00 PM</b>
------------------------------	--------------------------	-----------------------------

could be

<b>Page 13: [16] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 2:59:00 PM</b>
------------------------------	--------------------------	-----------------------------

in which testing was possible

<b>Page 13: [16] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 2:57:00 PM</b>
------------------------------	--------------------------	-----------------------------

the

<b>Page 13: [16] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 2:57:00 PM</b>
------------------------------	--------------------------	-----------------------------

of two probands

<b>Page 13: [17] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 2:56:00 PM</b>
------------------------------	--------------------------	-----------------------------

missense

<b>Page 13: [17] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 2:57:00 PM</b>
------------------------------	--------------------------	-----------------------------

in *AIPPLI*

<b>Page 13: [17] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 5:20:00 PM</b>
------------------------------	--------------------------	-----------------------------

describing

<b>Page 13: [18] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 5:21:00 PM</b>
------------------------------	--------------------------	-----------------------------

these

<b>Page 13: [18] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 5:20:00 PM</b>
------------------------------	--------------------------	-----------------------------

changes

<b>Page 13: [18] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 5:20:00 PM</b>
------------------------------	--------------------------	-----------------------------

mutations

<b>Page 13: [18] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:00:00 PM</b>
------------------------------	--------------------------	-----------------------------

with LCA

<b>Page 13: [18] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:04:00 PM</b>
------------------------------	--------------------------	-----------------------------

both

<b>Page 13: [19] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 5:22:00 PM</b>
------------------------------	--------------------------	-----------------------------

compound heterozygous

<b>Page 13: [19] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 6:24:00 PM</b>
------------------------------	--------------------------	-----------------------------

an individual

<b>Page 13: [19] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:01:00 PM</b>
------------------------------	--------------------------	-----------------------------

all

<b>Page 13: [19] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:06:00 PM</b>
------------------------------	--------------------------	-----------------------------

CORS-1,

1			
2			
3	<b>Page 13: [20] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:07:00 PM</b>
4	the		
5			
6	<b>Page 13: [20] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:07:00 PM</b>
7	gene		
8			
9	<b>Page 13: [20] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 5:23:00 PM</b>
10	in <i>CEP290</i>		
11			
12	<b>Page 13: [21] Deleted</b>	<b>UGent</b>	<b>4/9/2010 11:58:00 AM</b>
13	,		
14			
15	<b>Page 13: [21] Deleted</b>	<b>UGent</b>	<b>4/9/2010 11:58:00 AM</b>
16	and <i>RPGRIP1</i> (1%)		
17			
18	<b>Page 13: [22] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 5:24:00 PM</b>
19	through		
20			
21	<b>Page 13: [22] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 5:25:00 PM</b>
22	analysis		
23			
24	<b>Page 13: [22] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 2:41:00 PM</b>
25	The two variants identified in <i>CRX</i> had an uncertain pathogenic potential and were therefore not		
26	included in these calculations.		
27			
28	<b>Page 13: [23] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 6:38:00 PM</b>
29	31		
30			
31	<b>Page 13: [23] Deleted</b>	<b>Frauke Coppieters</b>	<b>6/16/2010 5:25:00 PM</b>
32	variants/		
33			
34	<b>Page 13: [23] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:09:00 PM</b>
35	patients with LCA, EORD, SLS, LCA-JS or CORS		
36			
37	<b>Page 13: [23] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 3:08:00 PM</b>
38	. Segregation and thorough bioinformatic evaluation allowed interpretation of these variants		
39			
40	<b>Page 13: [23] Deleted</b>	<b>Frauke Coppieters</b>	<b>4/16/2010 1:03:00 PM</b>
41	Table 2		
42			
43	<b>Page 13: [24] Deleted</b>	<b>UGent</b>	<b>4/9/2010 12:10:00 PM</b>
44	the		
45			
46	<b>Page 13: [24] Deleted</b>	<b>UGent</b>	<b>4/9/2010 12:10:00 PM</b>
47	in		
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			